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SUMMARY 
Mesenchymal stem cells (MSCs) have been identified in several adult tissues and have the 
ability to differentiate into multiple cell types. However, not all MSC types differentiate 
efficiently into all lineages. We show here that there is an epigenetic basis for this restricted 
differentiation capacity. DNA methylation was determined on lineage-specific promoters by 
bisulfite sequencing, and genome-wide by methyl DNA immunoprecipititation (MeDIP) with 
promoter array hybridization in mesenchymal stem cells (MSCs) of various tissues. Bisulfite 
sequencing shows that the adipogenic FABP4 and PPARG2 promoters are differentially 
methylated in ASCs and bone marrow (BM) MSCs relative to Wharton’s jelly (WJ) MSCs 
and muscle progenitor cells (MPCs). In contrast, the myogenin (MYOG) promoter is 
hypomethylated in WJMSCs and MPCs relative to ASCs and BMMSCs. In hematopoietic 
stem cells (HSCs), all promoters are hypermethylated. Differential methylation correlates 
with distinct differentiation capacities: ASCs and BMMSCs differentiate efficiently into 
adipocytes but not into multinucleated myogenin positive myocytes, whereas MPCs display 
poor adipogenic differentiation but robust myogenic capacity. The endothelial CD31 gene is 
methylated in ASCS, BMMSCs, WJMSCs and MPCs, in agreement with their poor 
endothelial differentiation potential. CD31 is however unmethylated in HSCs, in which its 
expression can be induced. Methylation patterns in adipocytes, muscle and endothelial cells 
argue that ASCs (and BMMSCs) are epigenetically pre-programmed for adipogenesis, while 
MPCs have a methylation pattern predictive of myogenic potential. Bisulfite sequencing 
corroborates genome-wide methylation profiling. MeDIP reveals similarity in methylation 
profiles between MSCs from adipose tissue, bone marrow and muscle, reflecting the 
mesodermal origin of these cells. Our results put forward the hypothesis that DNA 





1. STEM CELLS 
Stem cells are unspecialized cells that have the ability to self-renew (self-renewal capacity) 
and to give rise to at least one more committed progenitor or differentiated cell type 
(differentiation capacity). Stem cells can be classified according to their differentiation 
potential as totipotent, pluripotent, multipotent and unipotent; this differentiation potential, or 
“stemness”, is likely to exist as a continuum, or gradient, in the organism or tissue in which 
they reside (Fig. I-1). In mammals, only the zygote and cells of the cleavage-stage embryo 
are totipotent (up to the 4-8 cell-stage) and can generate an entire organism, including 
extraembryonic tissues. Embryonic stem cells (ESCs) are derived in vitro from culture of the 
inner cell mass, the group of cells that give rise to the embryo itself (Evans and Kaufman, 
1981; Thomson et al., 1998). ESCs are pluripotent and can give rise to all cell types derived 
from the three embryonic germ layers – mesoderm, endoderm and ectoderm, in chimeric 
mice. These three germ layers are the embryonic source of all cells of the body. Multipotent 
stem cells can generate several cell types within a lineage, and their differentiation capacity if 
often restricted to one germ layer. Unipotent stem cells contribute only to one mature cell 
type, and should perhaps be referred to as progenitor cells.  
 
Fig. I-1. A gradient of stemness. As 
differentiation proceeds, the differentiation 
capacity of stem and progenitor cells along the 
gradient decreases.  
 
Multipotent somatic adult stem cells, often commonly referred to as adult stem cells, 
are found in many different organs and tissues such as bone marrow, central nervous system, 
muscle, liver, dermis, epidermis, gastrointestinal tract, retina, adipose tissue, dental pulp and 
blood (Serafini and Verfaillie, 2006; Keating, 2006) (Fig. I-2). The origin of somatic stem 
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cells in mature tissues remains elusive and it is often difficult to distinguish adult, tissue-
specific stem cells from progenitor cells on the basis of expression of specific surface 
markers. The term somatic stem cell plasticity describes the ability of tissue-specific stem 
cells to acquire, under certain microenvironmental conditions, the fate of cell types different 
from the tissue of origin. Somatic stem cells are rare in most tissues. As an example, 1 in 
~15,000 cells in the bone marrow is a 
hematopoietic stem cell (HSC). The 
primary functions of tissue-specific 
somatic stem cells are to maintain the 
steady state functioning of a tissue 
(homeostasis) and with limitations, to 
replace cells that die because of disease 
or tissue injury (Baksh et al., 2004; 
Serafini and Verfaillie, 2006).  
 
Fig. I-2. Multilineage differentiation 
capacity of bone marrow and neuronal stem 
cells (source: http://stemcells.nih.gov). 
 
1.1. Mesenchymal stem cells 
Mesenchymal stem cells (MSCs), also called stromal stem cells or mesenchymal stromal 
cells reside in the stroma of most organs. The stroma is the connective framework of a tissue, 
while the mesenchyme is connective tissue of mesodermal origin. MSCs were first described 
as bone-forming progenitors in bone marrow (Friedenstein et al., 1968) Early cultures of non-
adipocytic cells from brown adipose tissue (MASTERS, 1965) and an early report of 
“fibroblast-like transformation of human bone marrow fat cells in vitro” (Miyoshi et al., 
1966) suggest that also other laboratories were at that time studying a mesenchymal 
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population of cells that could be cultured and whose phenotype was able to change. MSCs 
have since been described and characterized from various adult mesenchymal tissues such as 
bone marrow (Pittenger et al., 1999), adipose tissue (Zuk et al., 2001; Katz et al., 2005; 
Boquest et al., 2005), umbilical cord (Wang et al., 2004), cord blood (Lee et al., 2004a), 
amniotic fluid (in 't Anker et al., 2003), peripheral blood (Gronthos et al., 1994), dermal 
tissue and skeletal muscle (Williams et al., 1999).  
The diversity of tissue sources from which MSCs have been isolated, and the use of 
various isolation methods have led to the proposal of three criteria that define multipotent 
MSCs by the International Society for Cellular Therapy. First MSCs should adhere to plastic 
and form fibroblast-like colonies (CFU-Fs) in standard culture conditions. Second, ≥95% of 
the MSC population must express CD105 (endoglin), CD73 and CD90 (Thy-1) on the 
surface, measured by flow cytometry. Additionally, less than 2% of these cells should 
express the hematopoietic markers CD45, CD34, CD14 or CD11b, CD79α and CD19 and 
HLA class II. Adult MSCs are reported to express intermediate levels of major 
histocompatibility complex (MHC) class I but do not express human leukocyte antigen (HLA 
class II) unless stimulated by, e.g., interferon-γ (Le et al., 2003). MSCs are devoid of the 
endothelial cell marker CD31 (Chamberlain et al., 2007). Third, the cells should be able to 
differentiate into osteoblasts, adipocytes and chondroblasts in vitro.  
Indeed, MSCs can differentiate in vitro and in vivo along certain mesenchymal 
lineages such as adipocytic, osteoblastic and chondrocytic lineages. They may also give rise 
to skeletal and cardiac muscle cells and to endothelial cells (Pittenger et al., 1999; Serafini 
and Verfaillie, 2006). A subset of MSCs may also give rise to neuronal or hepatic 
differentiated cell types (Sanchez-Ramos et al., 2000; Weng et al., 2003; Boquest et al., 
2005; Krabbe et al., 2005).  
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Plastic-adherent cell populations isolated from bone marrow and adipose tissue 
contain cells with various differentiation capacities (Pittenger et al., 1999; Zuk et al., 2002; 
Katz et al., 2005; Boquest et al., 2005; Kucia et al., 2005). This heterogeneity, together with 
the ability of MSCs to change in response to their environment, contributes to the difficulty 
to identify a unique MSC phenotypic fingerprint. The monoclonal antibody STRO-1 has been 
used to identify clonogenic bone marrow MSCs (Gronthos et al., 1994), but MSCs also 
express a number of surface markers, none of which are specific to MSCs (Dominici et al., 
2006). While surface marker and gene expression profiles are being mapped by many 
research groups for various types of MSCs, variability in their differentiation potential has 
sparked studies on the identification of other markers, such as epigenetic marks associated 
with lineage-specification genes, that may define MSC subsets (Eckfeldt et al., 2005). Some 
of this work is ongoing in our laboratory and the present work addresses the epigenetic 
makeup of human MSCs from several tissues. 
 
1.2. Bone marrow mesenchymal stem cells 
Multipotent MSCs derived from the stroma of bone marrow (BMMSCs) have the capacity to 
contribute to the regeneration of mesenchymal tissues such as bone, cartilage, muscle, 
ligament, tendon, adipose and stroma (Pittenger et al., 1999). In vitro, BMMSCs can 
differentiate into adipogenic, chondrogenic and osteogenic lineages as well as into skeletal 
myocytes, neurons and endothelial cells (Wakitani et al., 1995; Woodbury et al., 2000; Reyes 
et al., 2001). The immunophenotype of BMMSCs has been well characterized but is not 
necessarily unique for this cell type (Pittenger et al., 1999; Chamberlain et al., 2007). 
Moreover, BMMSCs secrete growth factors, interleukins, cytokines and chemokines, some of 
which are only expressed after stimulation. MSCs also express growth factor receptors, 
adhesion molecules and matrix molecules including fibronectin, laminin, collagen and 
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proteoglycans (Minguell et al., 2001). These data sustain the view that BMMSCs contribute 
to the formation and function of a stromal microenvironment in bone marrow. This 
microenvironment produces inductive and regulatory signals for development of 
hematopoietic progenitors and other non-mesenchymal stromal cells (Klein, 1995; Minguell 
et al., 2001).  
  
1.3. Mesenchymal stem cells from adipose tissue 
1.3.1. Phenotypic characteristics of adipose stem cells 
The stromal-vascular fraction of subcutaneous adipose tissue contains a cell population that 
displays multilineage developmental plasticity in vitro and in vivo (Zuk et al., 2001). 
Multipotent adipose stem cells (ASCs) differentiate into adipogenic (Fig. I-3A), osteogenic 
(Fig. I-3B-D), chondrogenic (Fig. I-3E) and myogenic cell types, as well as along 
endothelial (Fig. I-3F) and neuronal (Fig. I-3G) lineages (Zuk et al., 2001; Halvorsen et al., 
2001; Zuk et al., 2002; Erickson et al., 2002; Safford et al., 2002; Gimble and Guilak, 2003; 









Fig. I-3. In vitro and in vivo differentiation of human ASCs. (A) Adipogenic differentiation (Oil Red-
O staining). (B) Osteogenic differentiation (Alizarin red staining). (C,D) Ectopic bone formation in 
mouse muscle (arrows). (E) Chondrogenic differentiation (Toluidine blue staining). (F) Endothelial 
differentiation. (G) Neurogenic differentiation (immunostaining for IF-200). (A. Boquest, and P. 
Collas, unpublished data).  
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ASCs are similar but not identical to BMMSCs in various aspects. In culture, ASCs 
express surface markers similar to those expressed by BMMSCs, including CD105, CD73, 
CD90, CD44 and Stro-1, and do not express CD45 and CD31 (De Ugarte et al., 2003; 
Boquest et al., 2005; Strem et al., 2005; Fraser et al., 2006). BMMSCs however express 
different adhesion molecules with function in homing and mobilization of HSCs (De Ugarte 
et al., 2003; Strem et al., 2005; Fraser et al., 2006), suggesting different homing properties 
for BMMSCs and ASCs. Notably, ASCs express the adhesion molecule integrin very late 
antigen CD49d (VLA4) but not CD106, whereas BMMSCs express CD106 but not CD49d 
(Boquest et al., 2005). Another difference of practical significance is yield: in human bone 
marrow, only 0.001-0.01% of nucleated cells form CFU-Fs (Pittenger et al., 1999) while 
adipose tissue harbors a large number of cells with CFU-F ability (Zuk et al., 2002). Our 
laboratory has purified uncultured ASCs before plating, using antibodies to select against 
CD45+ and CD31+ cells from the stromal-vascular fraction (Boquest et al., 2005). Up to 20 
million ASCs per 300 ml lipoaspirate can be harvested in this manner.  
ASCs constitute an attractive source of MSCs because they are abundant, easily 
purified, they do not require culture for isolation, unlike BMMSCs (Boquest et al., 2005), and 
they show higher CFU-F ability than BMMSCs (Strem et al., 2005; Kern et al., 2006). ASCs 
also share the perceived therapeutical advantages of BMMSCs because they are also non-
immunogenic (McIntosh et al., 2006; Uccelli et al., 2007) and they secrete cytokines 
supporting angiogenic and hematopoietic responses (Kilroy et al., 2007).   
The similarity of surface proteins expressed in MSCs from bone marrow or fat 
indicates that identifying a marker associated with the sub-population of highest 
differentiation potential among MSCs requires more than immunophenotyping. Gene 
expression profiling indicates that the transcriptome of ASCs and BMMSCs is similar (Lee et 
al., 2004b; Boquest et al., 2005), although minor differences have been claimed (Wagner et 
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al., 2005). Despite intensive efforts, therefore, a marker that distinguishes MSCs with di-
lineage, tri-lineage or higher differentiation capacity remains to be found. Another layer of 
analysis involves epigenetics: The present work addresses the question of whether the 
differentiation capacity of MSCs can be related to distinct epigenetics marks on genes that 
are expressed, repressed, or repressed with a potential for activation. 
 
1.3.2. Expansion and differentiation capacity of adipose stem cells 
In vitro, ASCs can be expanded as polyclones or single cell-derived clones in long-term 
culture and retain a normal DNA content (Meza-Zepeda et al., 2007).ASCs we have used in 
our laboratory senesce after 30-50 population doublings, in consistency with other reports 
(Stenderup et al., 2003; Bonab et al., 2006). The culture medium is supplemented with 10-
20% fetal calf serum (FCS), although proliferation capacity is enhanced with bovine 
fibroblast growth factor (FGF) and epidermal growth factor (EGF). Polyclonal ASCs cultures 
were used in the present work. 
Evidence suggests that ASCs can improve the function of damaged tissues in vivo. 
ASCs have been reported to differentiate into adipocytes, bone (A. Boquest and P. Collas, 
unpublished data; Fig. I-3C,D) and cartilage (Fraser et al., 2006).  ASCs may also 
incorporate into myofibers in injured muscle (Bacou et al., 2004) and engraft within an 
infracted myocardium (Planat-Benard et al., 2004). However, whether ASCs can truly form 
functional tissues of non-mesodermal lineages (Cousin et al., 2003; Kim et al., 2003; Kang et 
al., 2003) remains to be carefully addressed. 
  ASCs may also differentiate toward the endothelial lineage. In vitro, ASCs can form a 
cellular network expressing endothelial markers (Planat-Benard et al., 2004; Miranville et al., 
2004; Rehman et al., 2004; Cao et al., 2005). Freshly isolated ASCs express low levels of 
endothelial transcripts such as CD144 (CDH5) and CD31 (PECAM1) (Boquest et al., 2005), 
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suggesting a potential for endothelial differentiation. ASCs can also release angiogenic 
factors (Rehman et al., 2004; Nakagami et al., 2005). After transplantation, ASCs promote 
re-vascularization of ischemic tissue either directly (Planat-Benard et al., 2004; Miranville et 
al., 2004; Miyahara et al., 2006) or by secretion of angiogenic cytokines (Rehman et al., 
2004; Nakagami et al., 2005; Kilroy et al., 2007). We have shown that the differentiation 
capacity of human ASCs to endothelial cells in vitro is limited, as judged by the absence of 
significant upregulation of CD144 and CD31 (Boquest et al., 2007). This limitation may be 
imposed by the highly methylated state of the CD31 promoter in these cells (Boquest et al., 
2007).  
 
1.4. Wharton’s jelly mesenchymal stem cells 
The mucoid connective tissue of the umbilical cord, the Wharton’s jelly (WJ), is a rich source 
of MSCs. WJMSCs have been isolated from three relatively indistinct regions in the 
Whartons’s jelly, namely the perivascular zone, the intervascular zone and the subamnion 
(Troyer and Weiss, 2008a) (Fig. I-4). Cells in human Wharton’s jelly are not evenly 
distributed. The most immature cells are located in the intervascular and subamniotic regions, 
having greater competence to resume proliferation, whereas the perivascular zone mainly 
contains differentiated myofibroblasts (Nanaev et al., 1997; Karahuseyinoglu et al., 2007). 
MSCs have also been isolated from umbilical cord blood and umbilical vein subendothelium. 
It is unknown if MSCs isolated from different compartments of the umbilical cord represent 
different cell populations (Troyer and Weiss, 
2008b). 
Fig. I-4.  Compartments of the umbilical cord. 
Wharton’s Jelly is the connective tissue 
surrounding the umbilical vessels and includes the 
intervascular and subamnion regions.   
 
 9
Human WJMSCs are CD45, CD34, CD14, CD31, and HLA class II negative while 
they express CD73, CD90, CD105, CD44 and HLA-class I, in consistency with MSCs from 
bone marrow and adipose tissue (Troyer and Weiss, 2008a). WJMSCs also express a low 
amount of Wnt-signaling molecules and higher telomerase activity than other somatic cells 
(Karahuseyinoglu et al., 2007; Baksh et al., 2007). These factors are key regulators of self-
renewal and pluripotency in stem cells suggesting that WJMSCs use similar regulatory 
mechanisms to ESCs, especially when dissociated from their microenvironment. WJMSCs 
expand faster and to a greater extent than adult-derived MSCs, suggesting that WJMSCs may 
be a more “primitive” stromal cell population (Karahuseyinoglu et al., 2007). 
WJMSCs have been induced to differentiate in vitro into adipocytes, chondrocytes, 
osteocytes, endothelial cells (Wu et al., 2007), and cells with characteristics of neurons (Fu et 
al., 2006), cardiomyocytes and skeletal myocytes (Wang et al., 2004; Conconi et al., 2006), 
and photoreceptor cells (Lund et al., 2007). Yet further work is needed to determine whether 
WJMSCs can engraft and display multipotency in vivo. The present work examines DNA 
methylation patterns on lineage-specific genes in human WJMSCs and to what extent these 
patterns correlate with their reported differentiation capacity.  
 
1.5. Muscle-derived stem cells 
In adult skeletal muscle, satellite cells are considered to be important for postnatal muscle 
growth and regeneration (Le and Rudnicki, 2007). Muscle satellite cells are quiescent, 
mononuclear cells located beneath the basal lamina of skeletal muscle fibers (Fig. I-5). Their 
self-renewal capacity has been demonstrated by transplanting single intact myofibers into 
radiation-ablated muscles to show that the donor satellite cells generate new satellite cells in 
the host (Collins et al., 2005). In response to muscle damage or disease-induced 
degeneration, they are activated and undergo a terminal differentiation program, giving rise 
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to multinucleated muscle fibers (Schultz and McCormick, 1994; Collins et al., 2005) (see 
Fig. I-9). The descendents of activated satellite cells, the muscle precursor cells (MPCs) or 
myoblasts, undergo multiple divisions before fusing and undergoing terminal differentiation. 
Satellite cells can differentiate into adipocytes and osteocytes in vitro (Asakura et al., 2001). 
Although surface markers expressed by mouse satellite cells have been identified, human 
satellite cells are less characterized (Peault et al., 2007). In consistency with other MSCs 
however, they do not to express CD34 in culture. Satellite cells also express several 
transcription factors required for myogenic differentiation (see below). 
 
Fig. I-5. Satellite cells reside in a 
specialized niche in adult skeletal 
muscle. (A) Electron micrograph of 
skeletal muscle showing one myocyte 
nucleus (MC) and a satellite nucleus 
(SC). (B) Drawing of (A) emphasizing 
that the satellite cell lies between the 
basal lamina (black arrowhead and 
green line) and the sarcolemma (white 
arrowhead and red line). Taken from 
(Shi and Garry, 2006).  
 
  Alternative sources of stem cells have been identified in skeletal muscle, including 
side-population (SP) cells, muscle-derived stem cells (MDSCs), blood-derived circulating 
AC133+ cells and vessel-associated stem cells and pericytes. SP cells are isolated by 
fluorescence-activated cell sorting (FACS) based on their capacity to exclude the DNA-
binding dye Hoechst 33342 via the ABC transporter, and are present in several adult tissues 
(Zhou et al., 2001). Muscle SP cells are unable to differentiate in vitro but they give rise to 
both differentiated cells and satellite cells when transplanted intramuscularly (Asakura et al., 
2002). Unlike satellite cells, SP cells can migrate in the blood stream after intravenous 
injection, home into muscle and contribute to muscle regeneration (Bachrach et al., 2006). 
MDSCs have been purified from adult muscle by successive replating combined with FACS 
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sorting (Huard et al., 2003). They have high self-renewal and proliferation capacity and can 
contribute to muscle regeneration (Payne et al., 2005). It remains unclear to what extent 
MDSCs are different from satellite cells, which has led to authors using either terminology. 
Muscle-derived AC133+ cells display myogenic differentiation capacity. AC133+ cells are a 
subpopulation of blood-derived circulating cells expressing the hematopoietic marker AC133 
(Torrente et al., 2004). Pericytes associated with blood vessels of skeletal muscle can also 
regenerate diseased muscle and contribute to long term muscle regeneration, as well as give 
rise to other mesodermal lineages (Minasi et al., 2002; Dellavalle et al., 2007). 
Cells with myogenic potential have also been derived from other tissues including 
bone marrow, brain and adipose tissue (Cossu and Biressi, 2005). However, the myogenic 
potential of BMMSCs, ASCs and neuronal stem cells remains questionable (see Results). The 
normal contribution of non-muscle cells to growing or regenerating muscle is probably minor 
and satellite cells are considered to play a major role in this process (Buckingham, 2006; Le 
and Rudnicki, 2007). 
 
1.6. Hematopoietic stem cells  
Hematopoietic stem cells (HSCs) are the best characterized multipotent stem cells. Human 
HSCs have been isolated from adult bone marrow, peripheral blood, umbilical cord, fetal 
liver and fetal bone marrow (Serafini and Verfaillie, 2006). HSCs give rise to all cell types of 
the lymphoid and myeloid lineages. A single HSC can self-renew and give rise to multiple 
progeny cells (Szilvassy et al., 1989; Nolta et al., 1996) that retain full lineage potential but 
have limited self-renewal capacity.  
Two classes of HSCs can be detected on the basis of surface antigens and self-renewal 
capacity. Long-term repopulating HSCs can reconstitute all blood cell lineages after 
transplantation in a lethally irradiated mouse over a long time. Most cells in this class are 
 12
multipotent progenitors (Bryder et al., 2006). Short-term HSCs are immediately able to 
regenerate all blood cell types in an irradiated mouse, but are not able to self-renew over long 
term (Morrison and Weissman, 1994; Serafini and Verfaillie, 2006).  
Human HSCs express CD45, CD34, c-kit and Thy1 but not other lineage markers 
(Verfaillie et al., 2002; Bryder et al., 2006). During early development, HSCs can leave their 
tissue of origin, circulate and relocate to an available niche elsewhere (Quesenberry et al., 
2005). Adult HSCs can also leave the bone marrow, circulate and return to bone marrow 
(Bhattacharya et al., 2006). Thus, based on their differentiation, migration properties and 
surface marker expression, HSCs represent a lineage clearly distinct from MSCs.  
 
1.7. The stem cell niche 
Stem cells reside within a defined microenvironment referred to as the stem cell niche (Fuchs 
et al., 2004; Jones and Wagers, 2008) (Fig. I-6). Intercellular signals provided by the niche 
regulate stem cell proliferation, localization, differentiation and survival. The niche is 
composed of the stem cells themselves and differentiated cell types that interact with the stem 
cells and with each other. Extracellular matrix proteins provide structure, organization and 
mechanical signals. Via blood vessels, systemic signals as well as inflammatory and other 
cells can be recruited to the niche, while 
neurons provide neural input (Fig. I-6). 
The niche is also believed to provide a 
milieu protective against toxins and 
irradiation (Jones and Wagers, 2008).  
 
Fig. I-6. A stem cell niche. The various cell 
types making up the niche and influencing 
stem cell fate are shown. Taken from (Jones 
and Wagers, 2008).  
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In the niche, the self-renewal and differentiation properties of stem cells are enabled 
by asymmetric cell division, a distinct feature of stem cells (Fuchs et al., 2004). Asymmetric 
cell division yields one stem cell daughter and one daughter cell committed to differentiation 
(Fig. I-7). Regulation of the balance between symmetric division (giving rise to two identical 
daughter stem cells) and asymmetric division is important for maintaining the proper stem 
cell number and providing the surrounding tissue with differentiated cells. Two models have 
been proposed to achieve asymmetric cell division (Knoblich, 2008). The first model relies 
on asymmetric distribution of fate determinants in the cell, which become segregated at 
mitosis (Fig. I-7A). A second model is based on extracellular signals which lead to 
orientation of the mitotic spindle perpendicular to the niche surface. At mitosis, only one 
daughter cell maintains contact with the niche and retains the ability to self-renew, while the 
other daughter cell acquires a committed phenotype (Fig. I-7B). The stem cell can also divide 
symmetrically, parallel to the niche, 
generating two stem cells. 
 
Fig. I-7.  Regulation of stem cell self-renewal in 
the niche. (A) An axis of polarity distributes cell 
fate determinants asymmetrically at mitosis. The 
mitotic spindle is oriented along the same 
polarity axis ensuring asymmetric segregation of 
the determinants. (B) A stem cell may also 
depend on a signal coming from the niche (red 
arrows). By orienting the spindle perpendicular 
to the niche surface, only one daughter cell 
receives the signal and maintains the ability to 
self-renew, while the other cell may differentiate. 
Taken from (Knoblich, 2008). 
 
Cell-cell adhesion proteins such as as cadherins and catenins are important for 
retaining stem cells in the niche (Song et al., 2002; Jones and Wagers, 2008). Several 
signaling pathways are also essential for stem cell function in the niche (Fuchs et al., 2004). 
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Notably, Wnt signaling plays a role both in proliferation and lineage specification (Kleber 
and Sommer, 2004). Notch signaling and the bone morphogenetic protein 
(BMP)/transforming growth factor β (TGFβ) superfamily are involved in stem cell plasticity 
(Fuchs et al., 2004) The JAK-STAT pathway is also involved in maintenance and 
differentiation of stem cells (Zhao et al., 2002). Thus, the balance of stemness, transient 
proliferation and differentiation involves many signaling pathways in the niche (Fuchs et al., 
2004). 
Niches in the Drosophila germarium and testis, the subventricular zone of the brain, 
the hair follicle, the intestinal crypt and the bone marrow have been well characterized (Fuchs 
et al., 2004). In bone marrow, HSCs are in close proximity to osteoblasts which, together 
with endothelial cell, play a role as HSC regulators (Porter and Calvi, 2008). Describing 
MSC niches has however been more difficult. Yet, it is within the cellular microenvironment 
in the bone marrow that BMMSCs are presumed to exist (Baksh et al., 2004). Several studies 
also support the perivascular nature of the MSC niche and that this localization throughout 
the body would provide access to all tissues (Shi and Gronthos, 2003; da Silva et al., 2006). 
ASCs are reported to associate with perivascular cells in adipose tissue (Zannettino et al., 
2008), thus pericytes may in fact be MSCs (Doherty and Canfield, 1999). The various sub-
compartments of stem cells in adult tissues are likely to be at the origin of the difficulty of 
identifying MSC markers, and of differences in differentiation potential reported in various 
studies.  
 
2. ADIPOGENIC AND MYOGENIC DIFFERENTIATION  
2.1. Adipogenic differentiation 
Differentiation of MSCs into adipocytes is a two-phase process (Rosen and MacDougald, 
2006). The first phase, determination, regulated by activation of several signalling pathways, 
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involves the commitment of a pluripotent stem cell to the adipocyte lineage. The stem cell is 
altered to a pre-adipocyte, which cannot be distinguished morphologically from its precursor 
but has lost the potential to differentiate into other cell types. In the second phase, terminal 
differentiation, the pre-adipocyte differentiates into a mature adipocyte (Rosen and 
MacDougald, 2006).  
Adipogenic differentiation is regulated by a network of transcription factors and co-
regulators that coordinate expression of many genes and proteins (Fig. I-8). Peroxisome 
proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-binding protein α (C/EBPα) 
are the master regulators of adipogenesis (Farmer, 2006). In culture, preadipocytes become 
cell density-inhibited. Upon adipogenic stimulation, the cells re-enter the cell cycle and 
progress through two rounds of division (Otto and Lane, 2005). During this time, the cells 
express adipogenic transcription factors and cell cycle regulators that enable expression of 
PPARγ and C/EBPα. The committed cells differentiate and acquire the machinery for lipid 
synthesis and transport, insulin sensitivity and 
secretion of adipocyte proteins. 
 
Fig. I-8. Induction of adipogenesis by a cascade of 
transcription factors. These can be activated in vitro 
by addition of insulin, glucocorticoids, cAMP-
elevating agents and serum. Taken from (Farmer, 
2006).  
 
PPARγ is a member of the nuclear-receptor superfamily and is necessary and 
sufficient to initiate adipogenesis (Tontonoz et al., 1994; Koutnikova et al., 2003). Two 
isoforms of PPARγ, PPARγ1 and 2 are induced during adipogenesis, however PPARγ1 is 
also expressed in other cell types (Rosen and MacDougald, 2006). PPARγ activates genes 
involved in fatty acid binding, uptake and storage, including aP2/FABP4 (fatty acid binding 
protein 4) and LPL (lipoprotein lipase).   
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 C/EBPα is a pleiotropic transcriptional activator of adipocyte-specific genes including 
LEP (leptin) by binding C/EBP elements (Otto and Lane, 2005). C/EBPα plays a role in 
maintaining PPARγ expression in adipocytes (Wu et al., 1999). Two other members of the 
C/EBP family, C/EBPβ and C/EBPδ induce C/EBPα and PPARγ expression (Clarke et al., 
1997). In turn, PPARγ, C/EBPβ and C/EBPδ co-activate C/EBPα. The cAMP regulatory 
element-binding protein CREB also participates in induction of C/EBPβ (Zhang et al., 2004), 
while C/EBPδ induction is facilitated by glucocorticoids (Cao et al., 1991). These processes 
explain why inducers of cAMP (isobutylmethylxanthine) and glucocorticoids 
(dexamethasone) are needed in the adipogenic differentiation medium (Fig. I-8). Other 
regulators of adipogenesis include SREBP1c (sterol regulatory element binding protein 1c) 
which in response to insulin induces PPARγ (Kim et al., 1998) and Krox20, induced by 
exposure to mitogens, which promotes expression of C/EBPβ (Chen et al., 2005). 
Transcription factors of the E2F family have also been shown to regulate adipogenesis (Fajas 
et al., 2002). Thus, adipogenesis involves a complex balance of factors.  
 
2.2. Myogenic differentiation 
Similarly to adipogenesis, myogenesis involves a series of differentiation steps leading to 
committed progenitors and to multinucleated myogenic cells. In adult muscle, satellite cells 
are mitotically quiescent and become activated in response to stress elicited by weight 
bearing, muscle damage or disease-induced muscle degeneration. Microenvironment-secreted 
growth factors also promote satellite cell activation (Le and Rudnicki, 2007). One key 
signaling molecule in satellite cells is sphingosine-1-phosphate, required for entry into the 
cell cycle (Nagata et al., 2006). 
 Myogenic progenitors express specific transcription factors at defined stages of 
myogenesis (Buckingham, 2006; Peault et al., 2007) (Fig. I-9). Pax7 is expressed in satellite 
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cells and myogenic precursor cells in vivo, and in primary myoblasts in vitro. Pax7 is 
essential for postnatal maintenance and self-renewal of satellite cells. Pax7 and its paralog 
Pax3 (Montarras et al., 2005) are key upstream regulators of myogenesis and induce 
expression of the myogenic determination gene MyoD (Buckingham, 2006; Peault et al., 
2007). Myf5 is expressed at low level in quiescent satellite cells and continues to be 
expressed upon activation (Buckingham, 2007). Co-expression of MyoD and Myf5 is 
required for activation of myogenin. The transcription factors myogenin and MRF4 (Myf6) 
control muscle differentiation, leading to cell fusion and multinucleated myofibers (Chen and 
Goldhamer, 2003). Notably however, differentiation of satellite cells is preceded by down-
regulation of the Pax genes, a process regulated by myogenin itself (with specificity for 
Pax7) (Olguin et al., 2007).  
The human muscle-derived cells used in this study were shown by quantitative 
reverse transcription polymerase chain reaction (RT-qPCR) to express MYF5, MYOD and 
MYOG at the transcript level, while at the protein level no myogenin expression was 
observed (see Results). Because PAX3 and PAX7 were not expressed, these cells were at or 
beyond the myoblast stage (Fig. I-9). 
We refer to these cells as MPCs.  
 
Fig. I-9. Myogenic differentiation. 
Distinct sets of genes are expressed 
at specific stages of myogenesis, 
enabling the distinction of four 
progenitor cell types. Taken from 




3. EPIGENETIC REGULATION OF GENE EXPRESSION: ROLE OF 
DNA METHYLATION 
3.1. Introduction to epigenetics 
Genomic DNA contains the central core of genetic information of the cell. Throughout 
development, distinct patterns of gene expression are set up in somatic cells, and stably 
inherited through cell division. These patterns must be specified by information apart from 
the primary DNA sequence (Meehan, 2003). Superimposed upon the DNA sequence is a 
layer of heritable epigenetic information. Epigenetic mechanisms refer to heritable 
modifications of DNA and chromatin that do not affect DNA sequence (Collas et al., 2007). 
Epigenetic modifications fall into two main categories: DNA methylation and histone 
modifications. In addition to epigenetic modifications, the positioning of transcriptional 
activators, transcriptional repressors, other chromatin remodelling complexes and small 
interfering RNAs on target genes also regulate gene expression (Kawasaki and Taira, 2004; 
Matzke and Birchler, 2005).  
  In the nucleus, DNA is packed into chromatin. The nucleosome is the fundamental 
unit of chromatin and consists of 147 base pairs of DNA wrapped around an octamer 
composed of 2 subunits of each of histone H2A, H2B, H3 and H4. The linker DNA between 
the nucleosomes is associated with histone H1. Histones and in particular their amino-
terminal tails protruding from nucleosomes are subject to post-translational modifications 
such as acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, ADP- 
ribosylation, deimination and proline isomerization (Kouzarides, 2007) (Fig. I-10A). In 
addition, chromatin may be modified by dynamic replacement of core histones by histone 
variants such as the deposition of histone H3.3 on transcriptionally active promoters (Mito et 
al., 2005; Mito et al., 2007). 
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Fig. I-10. Post-translational 
histone modifications. (A) 
Core histones can be 
methylated, acetylated, 
phosphorylated, 
ubiquitinated or sumoylated 
to modulate gene 
expression. (B) Site and 
nature of known 
modifications on the 
amino-terminal tails of H3 
and H4.  
 
 Epigenetic histone modifications are so far best characterized for H3 and H4, in 
particular lysine acetylation and methylation (Fig. I-10B). Lysine acetylation almost always 
correlates with transcriptionally active chromatin while lysine methylation can have different 
effect depending on which residue is modified. Methylation of histone H3 lysine 4 (H3K4) 
and H3K36 is associated with transcribed chromatin. In contrast, methylation of H3K9, 
H3K27 and H4K20 generally correlates with repression (Bernstein et al., 2007). In particular, 
di- and tri-methylation of H3K9 (H3K9m2, H3K9m3) and tri-methylation of H3K27 
(H3K27m3) elicit the formation of repressive heterochromatin through the recruitment of 
heterochromatin protein 1 (HP1) (Lachner et al., 2001) and polycomb group (PcG) proteins, 
respectively (Cao et al., 2002). Acetylation of histone tails neutralizes the charge interaction 
between the DNA backbone and the histone tail. Acetylated lysines are recognized by 
bromodomains within nucleosome remodelling complexes, creating a chromatin 
conformation accessible for transcription activators (Bernstein et al., 2007). Acetylation of 
H3K9 (H3K9ac) and H4K16 (H4K16ac), together with di- and tri-methylation of H3K4 
(H3K4m2, H3K4m3), are exclusively found in euchromatin, often in association with 
transcriptionally active genes (Struhl, 1998; Santos-Rosa et al., 2002).  
 Histone tail modifications are mediated by specific enzymes. Numerous histone acetyl 
transferases (HATs), histone methyltransferases (HMTs), histone deacetylases (HDACs) and 
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histone demethylases (HDMases) have been identified (Kouzarides, 2007). Enzymes have 
also been identified for phosphorylation, ubiquitination, sumoylation, ADP-ribosylation, 
deimination and proline isomerization (Kouzarides, 2007). Combinations of histone 
modifications create an enormous potential for functional responses; however, not all these 
modifications mark the same histone at the same time, and the modifications are dynamic and 
rapidly changing. 
 
3.2. DNA methylation 
Cytosine methylation on DNA in general is associated with long-term gene silencing. In 
vertebrates, DNA methylation occurs almost exclusively on cytosine-phosphate-guanine 
(CpG) dinucleotides. DNA methylation consists of the addition of a methyl group to position 
5 of cytosine in the CpG dinucleotide (Fig. I-11A). CpG methylation is symmetrical – it 
occurs on both strands (Fig. I-11B) – and targets isolated CpGs, clustered CpGs, or clustered 
CpGs within a CpG island. A CpG island is defined as a sequence in which the 
observed/expected CpG frequency is greater than 0.6, with a G+C content greater than 50%. 
The expected number of CpGs in a given 200-bp window is calculated as the number of C's 
in the window multiplied by the number of G's in the window, divided by window length 
(Gardiner-Garden and Frommer, 1987). This 200-bp window is moved across the sequence 
of interest at 1 bp intervals. Takai and Jones published in 2002 a more refined definition 
where regions greater than 500 bp, with a G+C content >55 % and an observed 
CpG/expected CpG ratio of 0.65, provide a more accurate association with 5’ regions of 
genes and excludes most Alu repeats (Takai and Jones, 2002). CpG islands are often found in 
the 5' regulatory regions of vertebrate housekeeping genes; they are often protected from 
methylation, enabling constitutive expression of these genes. A consequence of this 
protection from de novo methylation is that CpG islands can remain unmethylated even when 
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their associated gene is silent (Bird et al., 1987; Weber et al., 2007). Changes in CpG island 
methylation are often (but not always) associated with disease. CpG islands in the promoter 
of tumor suppressor genes are unmethylated in normal cells, whereas a hallmark of cancer is 
de novo methylation of these CpG 
islands, resulting in repression of tumor 
suppressor genes and triggering of an 
uncontrolled cell cycle (Robertson, 
2005).  
 
Fig.  I-11. Principles of DNA methylation. 
(A) Mechanism of DNA methylation. (B) 
CpG methylation is symmetrical. (C) DNA 
methylation contributes to long-term gene 
silencing. 
 
CpG methylation is catalyzed by DNA methyltransferases (DNMTs). The 
maintenance DNA methyltransferase DNMT1 specifically recognizes hemi-methylated DNA 
after replication and methylates the daughter strand, ensuring fidelity in the methylation 
profile after replication (Jaenisch and Bird, 2003). In contrast to DNMT1, DNMT3a and 
DNMT3b are implicated in de novo DNA methylation that takes place during embryonic 
development and differentiation (Turek-Plewa and Jagodzinski, 2005), as a means of shutting 
down genes whose activity is no longer required as cells differentiate. DNMT2 has to date no 
clear ascribed function in DNA methylation (Hermann et al., 2003), but may have 
cytoplasmic transfer RNA methyltransferase activity (Goll et al., 2006; Rai et al., 2007). 
DNMT3L is a DNMT-related protein with no DNA methyltransferase activity, but which 
physically associates with DNMT3a and DNMT3b and modulates their catalytic activity 
(Suetake et al., 2004). DNA methylation largely contributes to long-term gene silencing (Fig. 
I-11C) (Klose and Bird, 2006; Hoffman and Hu, 2006) and as such it is essential for 
development (Reik et al., 2001; Morgan et al., 2005).  
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DNA methylation patterns of somatic cells are established according to 
developmental program. In early mammalian development, the paternal genome is actively 
demethylated shortly after fertilization whereas the maternal genome is subsequently 
demethylated through several rounds of replication (Reik et al., 2001). Thereafter, genome-
wide re-methylation occurs rapidly in the blastocyst and results in the methylation pattern 
found in adult somatic cells. DNA methylation is also implicated in X chromosome 
inactivation (Hellman and Chess, 2007) and genomic imprinting (Tremblay et al., 1995). 
DNA demethylation and methylation during embryogenesis are tightly controlled and are 
important for viability of the embryo. It is the best evidence of demethylation in vivo so far. 
However, the mechanisms by which it occurs are unknown (Reik et al., 2001; Cortazar et al., 
2007). A thymine DNA glycosylase (removing thymine from G·T mispairs) has been 
suggested to have a 5-mC DNA glycosylase activity and function as a DNA demethylase, yet 
its role remains debated (Cortazar et al., 2007). In adult cells, alterations of DNA methylation 
are often associated with disease and are a hallmark of cancer (Jones and Baylin, 2002).  
 
3.3. Mechanisms of DNMT targeting to DNA 
Studies of de novo DNA methylation in cell culture model systems have suggested at least 
three possible means by which de novo methylation might be targeted (Fig. I-12). First, 
DNMT3a and b themselves might recognize DNA or chromatin via specific domains (Fig. I-
12A). In mouse cells, DNMT3 enzymes have been found to partially localize to regions of 
pericentromeric heterochromatin with the conserved PWWP (Pro-Trp-Trp-Pro) motif 
required for targeting to these regions. The PWWP domain may interact with DNA in a 
sequence independent manner (Qiu et al., 2002). Second, DNMT3s may be recruited through 
interactions with transcriptional repressors or other factors, which in turn are targeted to 
DNA or chromatin (Fig. I-12B). For example, the transcription factor Myc associates with 
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DNA methyltranseferase activity and a direct interaction between DNMT3a and Myc is 
required for efficient repression of the Myc target gene P21cip1 (Brenner et al., 2005). Other 
studies have shown that the nucleolar remodelling complex NoRC represses ribosomal DNA 
transcription and associates with DNMT3b and DNMT1 (Santoro et al., 2002; Santoro and 
Grummt, 2005). Third, short interfering RNAs may induce de novo DNA methylation and 
gene silencing (Fig. I-12C). For instance in plants, RNAi-mediated gene silencing results in 
transcriptional silencing often as a result of de novo methylation of the silenced gene (Matzke 
and Birchler, 2005). De novo DNA methylation during RNAi silencing in mammalian cells 
has also been reported (Morris et al., 2004; Kawasaki and Taira, 2004);  however these 
results remain controversial to date (Klose and Bird, 2006). Thus, an RNAi mechanism may 
also be responsible for DNMT targeting, at least in plants.  
Fig. I-12. Targeting de novo methylation. (A) 
The PWWP domain of DNMT3a and 
DNMT3b is required to target the 
methyltransferases to regions of 
pericentromeric heterochromatin. (B) 
Transcription factors (TF) have the capacity to 
interact with DNMTs to recruit 
methyltranseferase activity. (C) De novo DNA 
methylation might be targeted by 
transcriptional gene silencing (TGS) pathways 
that respond to RNAi signals. Taken from 
(Klose and Bird, 2006). 
 
3.4. Mechanisms of DNA methylation-dependent transcriptional gene silencing 
Several mechanisms have been proposed for DNA methylation-dependent repression of gene 
expression (Klose and Bird, 2006). (i) Cytosine methylation can directly interfere with 
transcription factor binding to cognate DNA sequences, and thereby inhibit transcription 
(Fig. I-13A). (ii) However, repression seems to occur largely indirectly, via recruitment of 
methyl CpG-binding domain (MBD) proteins that induce chromatin changes (Fig. I-13B). A 
mammalian methyl-CpG-binding protein was identified a “long” time ago (1989) (Meehan et 
al., 1989) and since, a family of five mammalian methyl-binding proteins (MBPs) sharing the 
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methyl-CpG-binding domain has been identified through bioinformatics (Hendrich and Bird, 
1998). MeCP2, MBD1, MBD2 and MBD4 all recognize methyl-CpG. MBD3 however 
contains amino acid substitutions that prevent binding to methyl-CpG. Kaiso is a novel MBP  
that lacks the MBD but recognize methylated DNA through zinc-fingers (Prokhortchouk et 
al., 2001). All MBPs can recruit chromatin remodelling co-repressor complexes to regions 
containing DNA methylation and mediate silencing of gene expression (Klose and Bird, 
2006). (iii)  DNMTs can, in addition to their enzymatic role, also interact with HMTs (Fuks 
et al., 2003; Geiman et al., 2004), HDACs (Fuks et al., 2000; Fuks et al., 2001; Geiman et 
al., 2004) and the ATP-dependent chromatin remodelling protein hSNF2H (Geiman et al., 
2004), and thereby induce chromatin modifications and transcriptional repression (Fig. I-
13C).  
(iv) Lastly, there are indications that DNA methylation is involved in the 
maintenance, rather than initiation, of gene silencing (Weber and Schubeler, 2007) (Fig. I-
13D). In a study of the epigenetic reprogramming of the Oct4 gene during differentiation of 
mouse ES cells, DNA methylation was found to be a late event and dispensable to initiate 
silencing, but was required to stably prevent re-expression of the gene (Feldman et al., 2006).  
The relationship between DNA methylation and gene expression is complex (Jones 
and Takai, 2001) and recent evidence based on genome-wide CpG methylation profiling 
highlights the CpG content of promoters as a component of this complexity (Weber et al., 
2007). It has been shown that sequences outside promoters have a high degree of DNA 
methylation. Thus in mammals most DNA outside regulatory regions (intergenic DNA, in 
genes, both intronic and exonic regions, and in repeat elements) appears to be methylated 
(Eckhardt et al., 2006; Weber and Schubeler, 2007). DNA methylation is consequently 
suggested to play a role in the global maintenance of the genome. For instance, a potential 
role for intragenic DNA methylation can be to inhibit cryptic transcriptional initiation outside 
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gene promoters. However, intragenic DNA methylation has also been suggested to reduce 
gene expression probably by reducing the capacity of RNA polymerase II (RNAPII) to 
transcribe through methylated regions (Fig. I-13D) (Klose and Bird, 2006). DNA 
methylation of transposable elements can lead to transcriptional inactivation and 
immobilization of these elements;  thus, DNA methylation is important for maintenance of 
genome stability (global hypomethylation is associated with increased genome instability) 
(Weber and Schubeler, 2007).  
 
Fig. I-13. Mechanisms of DNA 
methylation mediated repression. (A) 
DNA methylation can inhibit 
transcription factors binding to target 
sites and thereby directly inhibits 
transcription activation. (B) MBPs 
directly recognize methylated DNA 
and recruit co-repressors to silence 
transcription and modify surrounding 
chromatin. (C) DNMTs can interact 
with HMTs and HDACs to induce 
chromatin modifications and gene 
repression. (D) DNA methylation within the body of genes can reduce transcriptional elongation 
rates. MBPs might be involved, either directly or by their effects on the surrounding chromatin. Taken 
from (Klose and Bird, 2006). 
 
3.5. Methods for detecting DNA methylation 
There are a number of methods for studying cytosine methylation, including bisulfite 
genomic sequencing, methylation-sensitive restriction digestion, or immunoprecipitation of 
MBPs or anti-5-methylcytosine (5-mC) (Clark et al., 2006). In combination with DNA 
microarrays and high-throughput sequencing these are powerful tools for detection of DNA 
methylation on a genome-wide scale. Methylation-sensitive restriction enzyme-based 
methods utilize restriction enzymes, which either do not cleave their recognition site when it 
is methylated, or specifically digest methylated DNA. An important limitation is that these 
techniques are restricted to the analysis of methylation only within enzyme recognition sites. 
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Thus, two other strategies were used in this thesis, namely bisulfite genomic sequencing and 
immunoprecipitation of methylated DNA.  
In the bisulfite genomic sequencing approach, denatured DNA is treated with sodium 
bisulfite and a series of reactions convert unmethylated cytosines to uracil while methylated 
cytosines remain as cytosines (Fig. I-14A,B) (Clark et al., 2006). PCR amplification of 
converted DNA using primers to the region of interest replaces uracil with thymine and 
subsequent sequencing determines, by reading a thymidine or cytosine, the methylation state 
of the CpG dinucleotides in the original sequence (Fig. I-14A). This thesis has relied on 
bisulfite genomic sequencing to start unveiling the DNA methylation profile of tissue-
specific genes in human MSCs and HSCs. For our work, reverse sequencing was used to 
unveil either an adenine (A) corresponding to an unmethylated cytosine, or a guanine (G), 
corresponding to a methylated cytosine (Fig. I-14C). Bacterial cloning of the PCR products 
generates several sequences to provide a quantitative assessment of the extent of methylation 
of a given CpG. 
 
Fig. I-14.  Bisulfite genomic 
sequencing. (A) Overview of the 
procedure. (1) A DNA sequence (here, 
random) contains methylated and 
unmethylated cytosines in CpG 
dinucleotides (underlined). (2) Bisulfite 
treatment converts unmethylated Cs to 
Us while the methylated C is not 
converted. (3) PCR changes Us to Ts 
and (4) reverse sequencing identifies 
which cytosine was methylated and 
which was not in the original (top) 
sequence. (B) Reactions involved in the 
bisulfite conversion process. (C) 
Examples of sequences obtained after 
bisulfite conversion, PCR and reverse 
sequencing. Arrows in the top panel 
point to two As representing two 
unmethylated cytosines. Arrow in the 
bottom panel points to a G, representing 
a methylated C in the original sequence.  
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A second powerful strategy for analyzing DNA methylation relies on the enrichment 
of methylated DNA sequences by affinity purification. This is achieved either by 
immunoprecipitating MBPs, or, in the case of the present work, immunoprecipitating 
methylated DNA using a monoclonal antibody that specifically recognizes 5-mC (Weber et 
al., 2005; Zilberman and Henikoff, 2007). In the methylated DNA immunoprecipitation 
(MeDIP) assay (Fig. I-15), purified genomic DNA is fragmented to ~200-1,000 bp by 
sonication, and 5-mC enriched fragments are immunoprecipitated using anti-5mC antibodies. 
Fragmented input DNA remains untreated. Precipitated and input DNAs are amplified using 
a whole genome amplification kit and specificity of the immunoprecipitation is verified by 
PCR. For microarray-based analysis, such as that performed in this study, input DNA is 
labeled green with, e.g., Cy3 and MeDIP DNA is labeled red with Cy5 (Fig. I-15). In this 
study, MeDIP and the corresponding input DNA samples were co-hybridized onto a 
Nimblegen promoter array. A detailed account of the MeDIP procedure implemented in the 
laboratory as part of this work is provided in Materials and Methods and in the 




Fig. I-15. The MeDIP 
assay. Genomic DNA is 
purified from cells, 
fragmented to ~200-1,000 
bp by sonication, and 5-mC 
enriched fragments are 
immunoprecipitated using 
anti-5mC antibodies (α-
5mC Ab). Fragmented input 
DNA remains as is. 
Precipitated and input 
DNAs are amplified. 
Uniformity of amplified 
fragment size distribution is 
again assessed by agarose 
gel electrophoresis and 
specificity of the 
immunoprecipitation is 
verified by PCR. For array-
based analysis, such as that 
performed in this study, 
MeDIP and input DNA are 
differentially labeled. 
MeDIP and corresponding 
input DNA samples are co-
hybridized onto genomic 






FRAMEWORK AND AIMS OF THE STUDY 
 
MSCs, including ASCs, can differentiate into multiple cell types in vitro and in vivo. 
However, ASCs have a propensity to differentiate into primarily mesodermal lineages, and 
even so, their capacity to differentiate into non-adipogenic mesodermal pathways seems to be 
limited. With the aim of identifying an epigenetic basis for this restricted differentiation 
capacity, our research group has performed an analysis of DNA methylation at promoters of 
lineage-specific genes in ASCs and shown CpG hypomethylation of adipogenic promoters, in 
contrast to heavier methylation at non-adipogenic, lineage-specific promoters. 
The objective of this study was to test the hypothesis that the DNA methylation 
pattern on lineage-specific promoters in MSCs may constitute a predictor of 
differentiation potential.  
To test this hypothesis, we examined CpG methylation in selected promoters in 
different human MSC types such as adipose tissue-derived stem cells (ASCs), human muscle-
derived progenitor cells (MPCs), bone marrow MSCs (BMMSCs) and Wharton’s Jelly MSCs 
(WJMSCs). HSCs were also analyzed, together with differentiated adipocytes, skin 
fibroblasts, keratinocytes and DNA from a muscle biopsy.  
The specific aims of the study were to: 
1. Analyze by bisulfite genomic sequencing the DNA methylation profiles of 
adipogenic, myogenic and endothelial gene promoters in undifferentiated ASCs, 
BMMSCs, MPCs, WJMSCs and HSCs. 
2. Assess promoter DNA methylation changes upon adipogenic and myogenic 
differentiation of ASCs and MPCs, and compare these profiles to mature adipocytes 
and muscle, respectively. 
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3. Evaluate at the phenotypic and transcriptional level the differentiation capacity of 
ASCs and MPCs towards adipogenic and myogenic lineages.  
4. Implement and validate a methylated DNA immunoprecipitation (MeDIP) assay for 
genome-wide DNA methylation profiling of ASCs, BMMSCs, MPCs and HSCs. 
5. Carry out preliminary analyses of DNA methylation profiling in ASCs, BMMSCs, 
MPCs and HSCs 
 
In the course of this work, I have benefited from technical assistance from Kristin 
Vekterud. She has performed, specifically, bisulfite sequencing analyses of BMMSCs and 
WJMSCs (shown in Fig. R-2A), adipogenic-differentiated ASCs (shown in Figs. R-3A and 
R-8A), CD31+ SVF cells and HUVECs (shown in Fig. R-8A). She has also performed 
adipogenic and myogenic differentiation of BMMSCs (shown in Figs. R-4A and R-5C). All 





MATERIALS AND METHODS 
 
Cells  
ASCs were purified from the stromal vascular fraction of human adipose tissue as described 
earlier (Boquest et al., 2006b). In short, stromal cells were isolated from liposuction material 
by collagenase and DNase digestion, sedimentation and straining. CD45+ and CD31+ cells 
were removed by magnetic cell sorting to eliminate hematopoietic and endothelial cells, 
respectively, resulting in CD45-CD31- cells which were shown to have MSC properties 
(Boquest et al., 2005). Purified ASCs were plated overnight in DMEM/F12 containing 50% 
fetal calf serum (FCS) to facilitate adhesion and further cultured in DMEM/F12/10% FCS. A 
pool of ASCs from three donors (healthy women, aged 24-40) was used in this study. Cells 
were passaged with a split ratio of 1:3 by trypsinization and used at passage (P) 12. This 
polyclonal culture was shown to senesce at P30 (Noer et al., 2007). 
CD45-CD31+ endothelial progenitor cells were purified from adipose tissue by 
magnetic cell sorting and consisted of the positively sorted CD31+ cells of the stromal 
vascular fraction (see above) (Boquest et al., 2005). These cells were not cultured but rather, 
were analyzed as freshly isolated cells for DNA methylation (Boquest et al., 2005). The cells 
used in this study were isolated by Andrew Boquest in the laboratory prior to the start of this 
project.  
CD14-CD34+ BMMSCs (a gift from Aboulghassem Shahdadfar, Institute of 
Immunology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo) were isolated and 
cultured in DMEM/F12 supplemented with 20% FCS (Shahdadfar et al., 2005). Cells were 
used at P4 in this study and shown to senesce between P10 and 14 (not shown).  
HSCs were isolated from bone marrow (Steidl et al., 2004). Mononuclear cells were 
isolated by Lymphoprep (GE Healthcare; ww.gehealthcare.com) density gradient 
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centrifugation and resuspended in RPMI 1640. CD34+ cells were positively selected using 
magnetic beads (Direct CD34 Progenitor Cell Isolation Kit, Miltenyi Biotec; 
www.miltenyibiotec.com). Purity of the CD34+ HSCs was >97%, determined by flow 
cytometry. Purified HSCs were donated by Aboulghassem Shahdadfar. 
Primary cultures of MPCs derived from human muscle were purchased from Lonza 
(CC-2580 Muscle Myoblast Cell System; www.lonza.com). Cells were cultured in SkGM® 
Skeletal Muscle Medium (Lonza) and used at P7-P8 (this was necessary to obtain sufficient 
cell numbers, although cells reduced proliferation at P9; not shown).  
WJMSCs were derived in the laboratory of Mark Kirkland (Deakin University, 
Geelong, Australia) from umbilical cord explants. The outer membrane was manually 
removed, eliminating most of the subamnion, and blood vessels were dissected out, removing 
most perivascular cells. The intervascular tissue was digested with collagenase and dispase, 
and cells were sedimented, strained and plated. Although the resulting WJMSCs have not 
been characterized in detail (M. Kirkland, personal communication), we anticipate that the 
WJMSC culture contained primarily intervascular cells, with few, if any, perivascular cells. 
Cells were cultured for ~10 passages, DNA was isolated (see below) and sent to our 
laboratory.  
Human epidermal keratinocytes (Invitrogen; www.invitrogen.com) isolated from 
adult skin were cultured in Epilife® Medium containing keratinocyte growth complement 
(Invitrogen). Cells used were under P5. Human foreskin fibroblasts (SkFib) from a 12 year 
old male (American Type Culture Collection; www.atcc.org) were cultured in DMEM/10% 
FCS. Passage number was not known but the cells were not senescent. Differentiated SGBS 
(Simpson-Golabi-Behmel syndrome) human adipocytes (Wabitsch et al., 2001). Human 
umbilical vein cells (HUVECs) (Skovseth et al., 2007) were a gift from Gutthorm Haraldsen 
(Department of Pathology, Rikshospitalet-Radiumhospitalet Medical Center). 
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Undifferentiated pluripotent NCCIT human embryonal carcinoma cells (American Type 
Culture Collection) were derived from a testicular germ-cell tumor and cultured in RPMI 
1640/10% FCS (Taranger et al., 2005). Human T cells were purified from peripheral blood 
(Skålhegg et al., 1994) and donated by Heidi K. Blomhoff (Institute of Basic Medical 
Sciences, University of Oslo). A human muscle biopsy from the deltoid of a 12 year old male 
was provided by Gisèle Bonne (Institut de Myologie, Paris, France). The biopsy was 
collected as part of a muscle dystrophy project ongoing in Bonne’s laboratory.  
 
Adipogenic, myogenic and endothelial differentiation 
For adipogenic differentiation, ASCs, BMMSCs and MPCs were cultured to confluency in 
DMEM/F12/10% FCS and stimulated for 3 weeks with 0.5 mM 1-methyl-3 isobutylxanthine, 
1 µM dexamethasone, 10 µg/ml insulin and 200 µM indomethacin. Cells were stained with 
Oil Red-O to visualize lipid droplets (Boquest et al., 2005). Quantification of labeling was 
performed by extraction of the dye and measurement of absorbance at 500 nm (A500) in 
triplicate cultures.  
 For myogenic differentiation of MPCs, cells were grown to 70% confluency and 
cultured for 6 days in DMEM/F12 with 2% horse serum (Sigma-Aldrich) and 1% penicillin. 
For ASCs and BMMSCs, cells at ~70% confluency were cultured for 5 weeks in 
DMEM/F12/5% horse serum, 50 μM hydrocortisone and 1% penicillin (Zuk et al., 2001). 
Nuclei were stained using Hemacolor® (Merck; www.merck.com). The resulting purple 
color of nuclei was due to the interaction between eosin Y and an azure B-DNA complex.  
 
Immunofluorescence 
Cells were cultured and/or differentiated into myocytes on acid-washed glass coverslips, 
fixed with 3% paraformaldehyde for 15 min and permeabilized with 0.1% Triton X-100 for 
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15 min. Preparations were washed 2 x 5 min in PBST (PBS/0.01% Tween-20), proteins 
blocked in PBST/2% BSA for 15 min. Myogenin was detected using anti-myogenin antibody 
F5D (Santa Cruz;  sc-12732;  www.scbt.com) diluted 1:100 in PBST/2% BSA, and a Cy3-
conjugated anti-mouse IgG (Jackson ImmunoResearch; 15-165-044; 
www.jacksonimmuno.com) diluted 1:200 in PBST/2% BSA. DNA was counterstained with 
DAPI. Samples were observed on an Olympus BX51 epifluorescence microscope and images 
taken with an F-View CCD camera and Analysis 2.0 software (Soft Imaging System; 
ww.soft-imaging.net). For counting of myogenin-positive nuclei, at least 100 cells were 
counted in triplicates.  
 
Bisulfite genomic sequencing 
DNA was purified from cultured cells by phenol-chloroform-isoamylalcohol extraction and 
ethanol precipitation, and bisulfite-converted as described (Noer et al., 2006) according to a 
procedure I have set up in the laboratory. MethylEasy™ and MethylEasy Xceed™ kits 
(Human Genetic Signatures; www.geneticsignatures.com) were used indifferently, the 
MethylEasy Xceed™ kit being faster than MethylEasyTM. Converted DNA was amplified by 
PCR using primers designed with Methprimer (www.urogene.org/methprimer/index1.html). 
We designed primers to include the proximal promoter regions of four adipogenic genes 
(LEP, LPL, PPARG2, FABP4), one myogenic gene (MYOG) and one endothelial gene 
(CD31/PECAM-1). Primers to the 5’ end of exon 1 of MYOG were also designed. Primer 
sequences and amplicon sizes are given in Supplementary Table 1. The regions examined 
contained the transcription start site (TSS) or were immediately upstream of the TSS 
(Ensembl; www.ensembl.org/Homo_sapiens) (see Fig. R-1). PCR conditions were 95oC for 7 
min and 35-37 cycles of 95oC 1 min, 54/58oC 2 min and 72oC 2 min, followed by 10 min at 
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72oC. PCR products were cloned into E. coli by TOPO TA cloning (Invitrogen) and reverse-
sequenced (MWG Biotech; www.mwg-iotech.com). 
Methylation data are shown as filled (methylated CpG) or empty (unmethylated CpG) 
circles for each bacterial clone (rows). Each circle represents one CpG. Average methylation 
in promoter regions were compared pair-wise between cell types using a Fisher’s exact test 
and two-tailed P values. Numbers of methylated cytosines for a given CpG were compared 
between cell populations using unpaired t-tests and two-tailed P values.  
 
Reverse transcription (RT)-PCR 
Quantitative RT-PCR (RT-qPCR) was carried from 0.5 μg total RNA (Qiagen RNeasy; 
www.qiagen.com) using the Iscript cDNA synthesis kit (BioRad) and IQ SYBR® Green 
(Noer et al., 2006). PCR conditions were 95oC for 3 min and 40 cycles of 95oC for 30 sec, 
60oC for 30 sec and 72oC for 30 sec. qPCR data were analyzed (Pfaffl, 2001) using GAPDH 
as normalization control. Alternatively, 30 cycles were performed (end-point PCR) and 
products were resolved by 1% agarose gel electrophoresis. RT-PCR primers used are listed in 
Supplementary Table 1.  
 
Methylated DNA immunoprecipitation (MeDIP) 
The MeDIP protocol was implemented in the laboratory as one of the aims of this work (Fig. 
I-15). The protocol was adapted from that of Weber et al. (Weber et al., 2005; Weber et al., 
2007) and posted on the Epigenomic Network of Excellence website (http://www.epigenome-
noe.net/researchtools/protocol.php?protid=33). The protocol has been written in detail for 
publication (Supplementary Manuscript).  
In short, genomic DNA was purified by phenol-chloroform-isoamylalcohol extraction 
and ethanol precipitation, and fragmented to ~200-1,000 bp (enriched in 300-500 bp 
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fragments) by sonication (see Results). 5-methylcytosine (5-mC)-enriched fragments were 
immunoprecipitated using anti-5mC antibodies (Eurogentec cat. no. BI-MECY-1000; 
www.eurogentec.com). Precipitated and input DNA was amplified by 14 PCR cycles using 
the WGA2 Whole Genome Amplification kit (Sigma-Aldrich) and amplified DNA was 
cleaned up using the Qiagen MiniElute PCR Purification kit (www.qiagen.com).  
Following amplification, uniformity of fragment size distribution was again assessed 
by agarose gel electrophoresis and specificity of immunoprecipitation was verified by PCR 
using primers (Supplementary Table 1) to genes known to be unmethylated (housekeeping 
gene ubiquitin-conjugating enzyme E2B;  UBE2B) or methylated (H19 Imprinting Control 
Region;  H19ICR) in somatic cells (see Results). For hybridization to microarrays, input 
DNA was labeled with Cy3 (green) and MeDIP DNA was labeled with Cy5 (red).  
 
Microarrays 
Cy5-labeled methylated DNA-enriched fragments and Cy3-labeled input DNA fragments 
were co-hybridized onto Nimblegen human HG18 RefSeq Promoter arrays (cat. no. C4226-
00-01; www.nimblegen.com). Array design was built to cover over 24,000 human promoters, 
ranging from -2,200 to +500 bp relative to the TSS. Probes consisted of 385,000 50 to 85-
mers tiled throughout non-repetitive genomic sequences at an average spacing of 100 bp. 
Repeat sequences (centromeres) were masked. Sequence source for the probes was the UCSC 
Genome Browser (http://genome.ucsc.edu/). MeDIP and input DNA labeling, hybridization 
and detection were performed using the services of Nimblegen.  
 
MeDIP data analysis 
Methylation data were delivered by Nimblegen as xls and gff files. The latter were visualized 
using the Nimblegen SignalMap data browser version 1.9. The browser enabled interpretation 
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of tracks that included: scaled log2 ratios (log2 MeDIP/input signals), P-values, peaks, 
transcript localization and orientation, TSS, tiled region and nucleotide number.  
Signal intensity (raw) data: signal intensity data were extracted from the scanned 
images of each array using the NimbleScan extraction software. Signal intensities were saved 
in txt files, which is the raw data format for DNA methylation experiments. 
Scaled log2 ratio data: each feature on the array has a corresponding scaled log2 ratio, 
which is the ratio of the input signals for the “MeDIP” and “input” samples co-hybridized 
onto the array. The log2 ratio was computed and scaled to center the ratio data on zero. 
Scaling was performed by subtracting the bi-weight mean for the log2 ratio values for all 
features on the array from each log2 ratio value. Scaled log2 ratios were provided in gff files. 
P-value data: from the scaled log2 ratio data, a 750 bp window was placed around 
each consecutive probe and a one-sided Kolmogorov-Smirnov test was applied to determine 
if the probes were drawn from a significantly more positive distribution of intensity log2 
ratios than those in the rest of the array (the Kolmogorov–Smirnov test  is a goodness-of-fit 
test used to determine if two probability distributions differ, or, in the case of our data, 
whether a probability distribution (that of the log2 ratio) differs from a hypothesized 
distribution). The resulting score for each probe was converted into a -log10 P-value from the 
windowed test around that probe. P-value data files were in gff format.  
Peak data: peak data files were generated from P-value data files, by detecting peaks 
by searching for at least 2 probes above a P-value minimum cut-off of 2. Peaks within 500 bp 
of each other were merged. Peak data files were in gff format. 
CpG islands: to relate methylation profiles to CpG density, a CpG island track was 
provided. Peak height reflected CpG density in the island, while peak width defined the 
length of the CpG island.  
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Primary transcripts and TSS: positioning of primary transcripts, their orientation, and 
positioning of the TSS for each gene included on the array were provided.  
The time course of this project and current limitations in access to bioinformatics have 
not allowed the analysis of methylation profiles deeper than what was enabled with 
SignalMap. The required bioinformatics expertise is being developed at the Norwegian 
Microarray Consortium (NMC; www.mikromatrise.no) in collaboration with our laboratory 





Lineage-specific promoter regions examined by bisulfite sequencing 
We designed bisulfite-converted DNA-specific PCR 
primers to include the proximal promoter regions of 
four adipogenic genes (LEP, LPL, PPARG2, FABP4), 
one myogenic gene (MYOG) and one endothelial gene 
(CD31) (Fig. R-1).  
 
Fig. R-1. Genomic regions examined by bisulfite 
sequencing. TSS, transcription start site (+1). Numbers 
indicate nucleotide positioning relative to TSS. For 
MYOG, two amplicons were generated, overlapping 3 
CpGs. Length of the regions examined is indicated in bp.  
 
In the LEP (GenBank U43589) promoter, we analyzed 32 CpGs covering 361 bp 
ranging from nucleotides -277 to +84 relative to the TSS (+1). This region has been shown to 
be regulated by DNA methylation (Melzner et al., 2002). In the PPARG2 (GenBank 
AB005520) promoter, 6 CpGs were examined between nucleotides -620 to -149 relative to 
the TSS. The FABP4 (GenBank NM_001442) promoter region examined included 4 CpGs 
within nucleotides -478 to -65 upstream of the TSS. The LPL (GenBank X68111) promoter 
region examined spanned nucleotides -399 to +59 relative to the TSS and included 11 CpGs. 
The MYOG (GenBank X62155) region spanned nucleotides -414 to +376 relative to the TSS 
and included 31 CpGs. This region was covered by two amplicons (MYOG(P) [promoter] and 
MYOG(E1) [exon 1]) which shared 3 overlapping CpGs (Fig. R-1). We randomly chose to 
show all CpGs covered by MYOG(P) and remove the three 5’-most CpGs from MYOG(E1);  
these are shown in Supplementary Figure 1. The CD31 (GenBank X96848) promoter 
region examined spanned nucleotides -148 to +238 relative to the TSS and included 18 CpGs.  
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CpG methylation profiles of adipogenic promoters in ASCs, BMMSCs, MPCs, 
WJMSCs and HSCs  
We have previously established by bisulfite sequencing the DNA methylation profile of 
adipogenic promoters (LEP, LPL, FABP4 and PPARG2) in freshly isolated and cultured 
ASCs, to show that these promoters are largely unmethylated (Noer et al., 2006). Using a 
different polyclonal culture of ASCs, we corroborated, also by bisulfite sequencing, the 
hypomethylated state of these promoters (Fig. R-2A). We then compared these methylation 
profiles to those of BMMSCs and MPCs. Methylation profiles of LEP, FABP4 and PPARG2 
were similar in ASCs and BMMSCs and revealed mosaic hypomethylation (Fig. R-2A). Four 
CpGs (No. 1, 2, 11, 20; No. 1 being the 5’ most CpG examined) in LEP were more 
methylated in ASCs than in BMMSCs (P<0.001). Methylation in this region was also 
observed in our earlier work (Noer et al., 2006).  
In MPCs, the LEP promoter was also unmethylated, consistent with its localization in 
a CpG island (Fig. R-2A; Supplementary Table 2). FABP4 was strongly methylated in 
MPCs while PPARG2 was more methylated than in ASCs. In all promoters and in all cell 
types, methylation was mosaic between alleles, corroborating our previous findings (Noer et 
al., 2006) and reflecting the individual history of each cell in culture. We also examined the 
methylation of the same promoters in WJMSCs and HSCs. In both cell types, FABP4 and 
PPARG2 were hypermethylated relative to ASCs and BMMSCs whereas FABP4 methylation 
was similar to MPCs (Fig. R-2A; Supplementary Table 2). LEP was essentially 
unmethylated in WJMSCs but was hypermethylated in HSCs relative to all other cell types 
(Fig. R-2A; upplementary Table 2).  
Comparison of percentages of methylation (Fig. R-2B; Supplementary Table 2) 
indicates that LEP, FAPB4 and PPARG2 were globally more methylated in MPCs and HSCs 
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than in ASCs or BMMSCs, both of which displayed similar methylation percentages. FABP4 
and PPARG2 were also more methylated in WJMSCs than in ASCs and BMMSCs. The LPL 
promoter was unmethylated in all cell types examined, also consistent with its localization in 
a CpG island. Extent and pattern of CpG methylation in adipogenic promoters, therefore, 
may differ depending on the cell type examined.  
 
Fig. R-2. DNA methylation profile of adipogenic and myogenic promoters in ASCs, BMMSCs, 
MPCs, WJMSCs and HSCs. (A) Bisulfite sequencing analysis of CpG methylation in each promoter 
and on MYOG exon 1. Each dot depicts one CpG in the 5’–3’ order and each row of dots represents 
one bacterial clone (i.e., one genomic allele). Positioning of each CpG in each region is shown in Fig. 
R1. (B) Percentage of methylated CpGs in each region and for each cell type, determined from data in 
(A). Statistical comparisons within genes and between cell types are shown in Supplementary Table 2.  
 
Methylation profiles in the MYOG promoter and 5’ end of exon 1 of MYOG 
CpG methylation of the MYOG promoter (MYOG(P)) was mosaic and similar in ASCs and 
BMMSCs (Fig. R-2A). MYOG(P) was less methylated in MPCs and WJMSCs, but was 
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nearly 100% methylated in HSCs, except for CpG No. 2 which was unmethylated as in all 
other cell types (Fig. R-2A,B;  Supplementary Table 2).  
Interestingly, the MYOG(E1) region examined was consistently more methylated than 
the proximal promoter (Fig. R-2A). MYOG(E1) was strongly methylated in ASCs, 
BMMSCs, MPCs and HSCs, but displayed regions of low methylation in 60% of the alleles 
in WJMSCs (Supplementary Table 2). Furthermore, comparison of sequencing data for the 
three overlapping CpGs in the MYOG(P) and MYOG(E1) amplicons (Supplementary Fig. 
1A) showed that methylation was overall conserved, although some variation was detected 
for some CpGs in ASCs, WJMSCs (and fibroblasts) (Supplementary Fig. 1B). Thus, the 
MYOG promoter is more methylated in ASCs and BMMSCs than in MPCs and WJMSCs, 
and is nearly fully methylated in HSCs. One CpG (-335 nt from the TSS), however, is 
consistently unmethylated in all cell types.    
 
Methylation patterns are conserved in in vitro differentiated ASCs and SGBS 
adipocytes 
To determine the extent of epigenetic commitment of ASCs to adipogenesis, we compared 
the methylation profiles of differentiated ASCs to those of SGBS adipocytes. Methylation 
profiles and extent of methylation were similar for adipogenic and myogenic genes in 
undifferentiated ASCs, differentiated ASCs and SGBS adipocytes (Fig. R-3A-C). As 
suggested earlier (Noer et al., 2006), the hypomethylated state of adipogenic promoters may 




Fig. R-3. CpG methylation profiles in undifferentiated ASCs, in vitro adipogenic-differentiated ASCs 
and SGBS adipocytes. (A) Bisulfite sequencing data for SGBS adipocytes and adipogenic-
differentiated ASCs, at indicated loci. (B) Percentage of methylation in each region and for each cell 
type, determined from (A). (C) Methylation profile across the regions examined, determined from 
(A).  
 
In vitro adipogenic differentiation capacity of ASCs, BMMSCs and MPCs 
To put the methylation profiles identified in MSCs in a functional context, we determined the 
adipogenic differentiation capacity of ASCs, BMMSCs and MPCs. Cells were stimulated for 
three weeks toward adipogenesis and lipid droplets were stained with Oil Red-O. Both ASCs 
and BMMSCs efficiently differentiated into adipocytes, as shown by most cells containing 
lipid droplets (Fig. R-4A). In contrast, MPCs showed poor adipogenic differentiation. 
Quantification of Oil Red-O staining supported the visual picture (Fig. R-4B) and confirmed 
the strong adipogenic potential of ASCs and BMMSCs, but not of MPCs.  
Adipogenic differentiation was also evaluated by RT-PCR analysis of expression of 
adipogenic genes (LEP, LPL, FABP4, PPARG2) and, as a control for lineage-specificity, 
myogenic genes (PAX7, PAX3, MYF5, MYOD1, MYOG) after adipogenic induction. The 
adipogenic genes were not expressed at detectable levels in any of the undifferentiated cell 
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types (Fig. R-4C). Upon adipogenic differentiation, LPL, FABP4 and PPARG2 were 
upregulated (PPARG2 to a smaller extent) in ASCs and BMMSCs (Fig. R-4D). FABP4 and 
LPL transcripts (LPL at low level) were also detected in MPCs (Fig. R-4D), reflecting the 
differentiation of a minor proportion of the cells (see Fig. R-4A). Upregulation of LEP was 
not detected in any cell type. None of the myogenic genes examined were expressed in 
undifferentiated ASCs and BMMSCs and they were not induced after adipogenic 
differentiation (Fig. R-4C,D). MYF5, MYOD and MYOG were expressed in undifferentiated 
MPCs and their expression was maintained after adipogenic stimulation. PAX7 and PAX3 
were not expressed in undifferentiated MPCs but surprisingly, both were upregulated in 
adipogenic-stimulated cells, though at low levels (Fig. R-4C,D). As expected, PCR without 
RT to control of DNA contamination using MYOG and GAPDH primers gave no products 
(Fig. R-4C, -RT).  
Expression of adipogenic genes was also examined by quantitative RT-PCR for ASCs 
and BMMSCs, and confirmed end-point RT-PCR data (Fig. R-4E). LPL and FABP4 were 
strongly upregulated after adipogenic stimulation while PPARG2 showed more modest 
upregulation. In addition, LEP expression was detected by quantitative RT-PCR and showed 
a 4- to 5-fold upregulation after adipogenic stimulation; however CT values were over 30, 
indicative of low mRNA levels (data not shown) and accounting for the lack of LEP mRNA 
detection by end-point RT-PCR. Overall, our results indicate that ASCs and BMMSCs 





Fig. R-4. In vitro adipogenic differentiation of ASCs, BMMSCs and MPCs. (A) Oil Red-O staining 
of intracellular lipid droplets in ASCs, BMMSCs and MPCs before and after three weeks of 
adipogenic stimulation. Bars, 100 μm. (B) Quantification of Oil Red-O incorporation in 
undifferentiated cells and after adipogenic differentiation (mean±SD A500 of a triplicate experiment;  
**P<0.01 relative to undifferentiated cells;  t-test). (C) RT-PCR analysis of gene expression in 
undifferentiated ASCs, BMMSCs and MPCs. –RT, no reverse transcription reaction control. (D) RT-
PCR analysis of gene expression in ASCs, BMMSCs and MPCs after adipogenic stimulation as in 
(A). In (C) and (D), size markers are shown. (E) Real-time RT-PCR analysis of expression of 
indicated genes in adipogenic differentiated ASCs and BMMSCs, relative to their undifferentiated 
counterparts (level 1). 
 
 
In vitro myogenic differentiation of ASCs, BMMSCs and MPCs 
The predicted natural differentiation pathway of MPCs is myogenesis. Myogenic potential of 
MPCs was shown by their ability to differentiate into elongated multinucleated cells after 6 
days of myogenic sitmulation in horse serum (Fig. R-5A, Day 6). Control MPCs cultured for 
6 days in proliferation medium (containing FCS instead of horse serum) also showed an 
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elongated growth pattern, but there were no multinucleated cells (Fig. R-5A, Day 6, control). 
In contrast to MPCs, ASCs and BMMSCs stimulated under the same conditions showed no 
signs of myogenic differentiation after 5 weeks (Fig. R-5B). 
 We next analyzed myogenin protein expression by immunofluorescence using anti-
myogenin antibodies (Fig. R-5C). Undifferentiated MPCs, ASCs and BMMSCs did not 
express myogenin. Differentiation however induced myogenin expression in ~60% of nuclei 
(P<0.001 relative to Day 0;  Fig. R-5C) in MPCs. Day 6 control MPCs also displayed some 
myogenin expression, although in a lower proportion of nuclei (28%;  P<0.002;  Fig. R-5D). 
We observed no myogenin expression in stimulated ASCs and BMMSCs (Fig. R-5C), 
supporting the view that these MSC types have poor myogenic potential, at least under the 
conditions tested. 
To further evaluate the extent of myogenic differentiation of MSCs, we performed 
RT-PCR analysis of adipogenic and myogenic gene expression (Fig. R-5E; mRNA levels in 
undifferentiated cells are shown in Fig. R-4C). Undifferentiated MPCs did not express PAX7 
or PAX3 but expressed MYF5, MYOD and MYOG. The same transcript profiles were detected 
after myogenic stimulation (Fig. R-5E). Quantitative RT-PCR confirmed these data and 
showed small changes in gene expression upon myogenic differentiation (Fig. R-5F). In 
addition, ASCs and BMMSCs stimulated toward myogenesis upregulated LEP and LPL 
transcripts (FABP4 was also upregulated in BMMSCs), but not muscle-specific markers (Fig. 
R-5E). This may reflect a default differentiation pathway for these cells, possibly induced by 
confluency, as ASCs and BMMSCs grown to confluency spontaneously differentiate into 
adipocytes (data not shown). No adipogenic transcripts were detected in differentiated MPCs. 
Together with the phenotypic observations, these results argue that whereas MPCs have 
myogenic differentiation capacity in vitro, ASCs and BMMSCs are refractory to 
differentiation into myogenin-expressing multinucleated cells.  
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Fig. R-5. In vitro myogenic differentiation of MPCs, ASCs and BMMSCs. (A) Myogenic 
differentiation of MPCs. Cells at day 0 (prior to induction of differentiation), day 6 in differentiation 
medium and day 6 in control (proliferation) medium were stained with Hemacolor. Boxed areas are 
enlarged (bottom). Note the multinucleated cells at day 6 of stimulation. Bars, 100 μm. (B) Lack of 
myogenic differentiation of ASCs and BMMSCs after 5 weeks in myogenic differentiation medium;  
cells were stained with Hemacolor. Bars, 100 μm. (C) Immunofluorescence analysis of myogenin 
expression in MPCs, ASCs and BMMSCs induced to differentiate. Time points of analysis are 
indicated. Nuclei were counterstained with DAPI. Bar, 50 μm. (D) Proportion of myogenin-positive 
nuclei in myogenic-differentiated MPCs (n=100 per time point in each of a triplicate area). (E) RT-
PCR analysis of expression of indicated genes after myogenic stimulation of ASCs (5 weeks), 
BMMSCs (5 weeks) and MPCs (6 days). (F) Real-time RT-PCR analysis of expression of indicated 
genes in differentiated versus undifferentiated MPCs (level 1).  
 
DNA methylation patterns of adipogenic and myogenic promoters are similar in in vitro 
differentiated MPCs and muscle DNA 
To relate the DNA methylation patterns of adipogenic and myogenic genes in myogenic-
differentiated MPCs to that of muscle, bisulfite sequencing was performed on myogenic-
differentiated MPCs and on DNA isolated from a human deltoid biopsy from a 12-year old 
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male. Figures R-6A-C show that the LEP, FABP4, PPARG2 and MYOG promoters 
displayed similar methylation in both cell and tissue types. However, MYOG(E1) was 
hypermethylated in differentiated MPCs relative to muscle DNA, which showed a mix of 
hypomethylated and methylated alleles (Fig. R-6A,C). This suggests incomplete myogenic 
differentiation of MPCs in vitro. Methylation profiles of undifferentiated MPCs, myogenic-
differentiated MPCs and muscle DNA showed that differentiation maintained the MYOG 
methylation profile of undifferentiated cells (Fig. R-6C). These results suggest nonetheless 
that undifferentiated MPCs display epigenetic commitment to myogenesis, reflected by their 
DNA methylation pattern on the promoters examined.   
 
Fig. R-6. CpG methylation in undifferentiated MPCs, myogenic-differentiated MPCs and in a muscle 
biopsy. (A) Bisulfite sequencing data for muscle and myogenic-differentiated MPCs. (B) Percentage 
of methylated CpGs in each region, for each cell type, determined from (A). (C) Profile of CpG 
methylation determined from (A).  
 
 
Adipogenic and myogenic promoters show distinct CpG methylation patterns in 
keratinocytes and in skin fibroblasts 
Keratinocytes and foreskin fibroblasts are differentiated cells with no direct functional link to 
adipogenesis or myogenesis. Thus, to gain further insight on the lineage-specificity of the 
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methylation patterns observed in MSCs and HSCs, we examined the methylation of LEP, 
FABP4, PPARG2 and MYOG in keratinocytes and fibroblasts. These cells revealed different 
profiles (Fig. R-7). LEP was unmethylated in both cell types except for two CpGs methylated 
in fibroblasts. FABP4 was largely methylated in both cell types. PPARG2, however, was 
methylated in keratinocytes but largely unmethylated in fibroblasts. MYOG(P) and 
MYOG(E1) were hypermethylated in keratinocytes relative to fibroblasts. MYOG displayed a 
profile different from all other cell types examined in this study, with regions of 
hypermethylation in the promoter and low methylation of the first 9 CpGs in exon 1 (Fig. R-
7A,C). The relatively weaker promoter methylation in fibroblasts was not indicative of 




Fig. R-7. Methylation profiles in cultured primary keratinocytes and skin fibroblasts. (A) Bisulfite 
sequencing data for keratinocytes (Ker) and skin fibroblasts (SkFib). (B) Percentage of methylated 
CpGs determined from (A). (C) Profile of CpG methylation determined from (A).  
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The endothelial CD31 locus is methylated in MSCs and unmethylated in HSCs 
To ascertain the specificity of the methylation profiles obtained so far, we examined the 
methylation pattern in the endothelial CD31 proximal gene promoter and in the first 238 nt of 
exon 1 in MSCs, HSCs and in differentiated cells. CD31 is not known to be involved in 
adipogenic or myogenic differentiation, and thus was used as an “irrelevant” gene. The CD31 
proximal promoter (Fig. R-1) was methylated in ASCs, BMMSCs, MPCs and WJMSCs (Fig. 
R-8A,B;  Supplementary Table 2), BMMSCs revealed 5 unmethylated CpGs in exon 1. In 
contrast to MSCs, CD31 was unmethylated in HSCs, suggesting a different chromatin 
organization on this promoter in this cell type (Fig. R-8A,B). In differentiated cells, CD31 
was methylated in SGBS adipocytes, muscle, fibroblasts and T cells, although unmethylated 
alleles were also detected in T cells, reminiscent of the unmethylated state of HSCs (Fig. R-
8). Lastly, we verified that CD31 was largely unmethylated in HUVEC cells (Fig. R-8).  
These data were in agreement with our earlier results (Boquest et al., 2007), which also 
showed that CD31 appeared as hemimethylated in CD31+ cells isolated from the stromal 
vascular fraction of human lipoaspirates (Boquest et al., 2007) (see Fig. R-8A). This analysis 
indicates therefore that the CD31 promoter is methylated in MSCs and unmethylated in HSCs 
(P<0.001; Fig. R-8C; Supplementary Table 2). The unmethylated state of the CD31 
promoter in HSCs reflects a chromatin organization which is suggestive of endothelial 
differentiation potential, a possibility currently being tested in our laboratory. The 
unmethylated state of 5 CpGs in exon 1 in BMMSCs also suggests a distinct chromatin 
composition at this site, and perhaps also a potential for endothelial differentiation.  
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Fig. R-8. Methylation 
profile of CD31. (A) 
Bisulfite sequencing 
analysis of CD31 in 
indicated cell types. 
(B) Percentage of 
methylation of each 
CpG determined from 
data in (A). (C) 
Percentage of 
methylation in MSCs 
(blue) and 
differentiated cells 
(gray). ** P<0.01 
(Fisher’s exact tests) 
relative to the other 
cell types. 
Methylation profile of 
CD31+ SVF cells was 
taken from Boquest et 
al. (2007). 
 
Genome-wide DNA methylation profiling: establishment of a methylated DNA 
immunoprecipitation (MeDIP) assay 
To obtain a more global picture of the DNA methylation profile of ASCs, BMMSCs, MPCs 
and HSCs, we implemented a genome-wide strategy. We chose MeDIP because it can be 
combined with DNA hybridization to promoter arrays (Weber et al., 2005) which our 
laboratory also uses in ChIP-on-chip experiments. Genomic DNA was fragmented and 
methylated fragments were immunoprecipitated using anti-5mC antibodies. Detection of 
genomic regions of interest in the methylated DNA fraction was done by PCR (for 
validation) and by hybridization to Nimblegen promoter arrays. The MeDIP procedure is 
outlined in Figure I-15 and detailed in the Supplementary Manuscript.  
We performed several quality control tests as indicated in Figure I-15. First, we 
assessed sonication efficiency, which varies with DNA concentration, sonicator model (probe 
or bath), sonicator settings and time of sonication, and ensured homogenous fragment sizes 
between samples. Electrophoresis analysis shows that ASCs, BMMSCs and MPCs uniformly 
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showed high molecular weight DNA before sonication, and fragments of ~300-1,000 bp after 
sonication (Fig. R-9A).  
 Following immunoprecipitation, the yield of MeDIP DNA is low (~300-450 ng) and 
incompatible with array hybridization (which requires 2 μg DNA per array). Thus, a DNA 
amplification step of MeDIP and input DNA fractions was performed. To ensure uniformity 
of MeDIP and input DNA fragment sizes after amplification, electrophoresis analysis was 
also carried out. Both input and immunoprecipitated DNA displayed the recommended 
fragment sizes (~200-1,000 bp) (Fig. R-9B).  
 
Fig. R-9. Quality assessment of DNA in the MeDIP procedure. (A) Assessment of DNA 
fragmentation by sonication. Intact and sonicated DNA from ASCs, BMMSCs and MPCs were 
analyzed by agarose gel electrophoresis. (B) Assessment of input and MeDIP DNA fragment size and 
uniformity after amplification. Input and MeDIP DNA samples from ASCs, BMMSCs and MPCs 
were amplified, purified and resolved by agarose gel electrophoresis. (C) PCR analysis of MeDIP 
specificity. Input and MeDIP DNA were analyzed by PCR using primers for the H19 Imprinting 
Control Region (H19ICR), which is methylated in somatic cells but not in male germ-cell-derived 
embryonal carcinoma NCCIT cells, and for the UBE2B housekeeping gene promoter, which is 
unmethylated (Weber et al., 2007). DNA from ASCs, BMMSCs and NCCIT cells was used.  
  
Next, we verified by PCR that methylated DNA fragments were effectively 
immunoprecipitated by MeDIP. The imprinted H19ICR gene locus served as methylated 
control, and the housekeeping UBE2B gene promoter served as unmethylated control (Weber 
et al., 2007). Amplified MeDIP and input DNA from ASCs, MPCs and embryonal carcinoma 
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NCCIT cells (derived from a male germ-cell tumor and in which H19ICR was expected to be 
unmethylated), were tested. ASC and MPC samples gave H19ICR products, reflecting the 
methylated state of this locus in these cells (Fig. R-9C). However, MeDIP from NCCIT cells 
did not precipitate the H19ICR locus (Fig. R9C), confirming its unmethylated state in this 
cell type. UBE2B PCR was negative for all MeDIP samples, as expected from the 
unmethylated state of this housekeeping promoter (Weber et al., 2007). These observations 
indicate that DNA fragment sizes are uniform between replicates and cell types, and suggest 
that the immunoprecipitation is specific.  
 
Preliminary analysis of MeDIP results: introduction to data generated through 
NimbleScan and SignalMap 
Input and duplicate MeDIP DNA samples from ASCs, BMMSCs, MPCs and HSCs 
(Supplementary Fig. 2) were sent to Nimblegen for labeling and hybridization to promoter 
arrays. The NimbleGen SignalMap data browser enabled a visualization of the IP/Input log2 
ratio, P-values (expressed in –log10) computed from these ratios and methylation peak data 
generated from the P-values (see Materials and Methods).An overview of the information for 
chromosome 1 in one ASC sample is shown in Figure R-10A and a random segment shown 
in Figure R-10B. The genomic position of the regions examined is marked on top. Track 1 
displays the IP/input log2 ratio, with each bar representing the hybridization signal to one 
probe relative to the input (the 0 line). The ratios, therefore, reflect areas of hypomethylation 
(below the 0 line) and hypermethylation (above the 0 line) relative to genome average. From 
the log2 ratios, a statistical test reports the significance of positive enrichment (methylation), 
surrounding each probe within a 750 bp window, against all other probes on the array. The 
resulting score for each probe is the P-value, shown in track 2. Peak data (track 3) are 
generated from the P-value data by searching for at least 2 probes above a P-value of 2. 
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Peaks within 500 bp of each other are merged, which explains why there are fewer peaks than 
methylated regions detected by the P-value. Positions of transcripts are localized on track 4 
with the TSS on track 5.  CpG islands are marked on track 6, with the height of the peak 
reflecting CpG density and the width the area covered by the island. The tiled regions on the 
array are positioned on track 7. The probe-less area between nucleotides 122,000,000 and 
142,000,000 (Fig. R-10A) represents the centromere (no probes were made to DNA repeats). 
Several methylation profiles were observed in ASCs, with, as expected, an anti-
correlation between methylated areas and CpG islands (Fig. R-10B). The promoter regions 
shown displayed either strong or weak methylation, ith consistent unmethylation or 
hypomethylation over 200-400 bp around the TSS (Fig. R-10B). Unmethylated regions 
corresponded to CpG islands (Fig. R-10B), however unmethylated areas were also outside 
CpG islands (Supplementary Fig. 3). The different methylation patterns observed, on all 
chromosomes and each cell type (data not shown), reinforce the view that the MeDIP was 
specific.  
 
DNA methylation profiles are similar between MeDIP replicates, and between ASCs, 
BMMSCs, MPCs and HSCs 
To evaluate the technical reproducibility of the MeDIP procedure, duplicate MeDIPs were 
carried out from a single DNA preparation from ASCs, BMMCs, MPCs and HSCs. P-values 
on chromosome 1 showed similar methylation profiles for each replicate, arguing that MeDIP 
was reproducible (Fig. R-11A). Similar observations were made for all chromosomes (not 
shown). A scatter-plot analysis of reproducibility, currently being performed at the NMC 








Fig. R-10. SignalMap data from a MeDIP from ASCs, for chromosome 1. (A) DNA methylation 
profile of ASCs. Top, chromosome positioning. Track (1): scaled IP/input log2 ratios. Track (2): P-
values, expressed in –log10. Track (3): methylation peaks. Track (4): primary transcripts. Track (5): 
TSS. Track 6,: CpG islands. Track (7): tiled regions. The “blank” area covers the centromere and is 
devoid of probes. (B) Methylation profile for random 30-kb segment of chromosome 1. The same 
tracks as in (A) are shown. The genes represented are DPH2, ATPF6, B4GALT2 and CCD24 (left to 
right).  
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The methylation peaks, which provide a more stringent account of methylation, also 
revealed similarity between MeDIP replicates (Fig. R-11B). Yet, the profiles were not 
identical and some areas showed different peak profiles between replicates (e.g., region 
160,000,000 to 180,000,000 in MPC-1 and MPC-2; Fig. R-11B). However, –log10 P-values 
(Fig. R-11A) for the same region showed that the profiles were nearly identical, albeit with 
slightly lower values for MPC-1 than for MPC-2. As methylation peaks are defined from –
log10 P-values ≥2, MPC-1 shows fewer peaks than MPC-2 (Fig. R-11B). Thus, differences in 
methylation peak profiles are mostly due to differences in P-values. They do not however 
necessarily reflect true differences in methylation patterns (see Figs. R-11A, R-12). More 
advanced statistical analysis, underway at the NMC, is again required to assess the technical 
reproducibility of the assay.  
 To start comparing methylation profiles between cell types, we scanned P-value and 
peak profiles for all chromosomes in all cell types. Methylation profiles were similar but not 
identical (Figs. R-11A,B). Similarities between ASCs, BMMSCs, MPCs and HSCs were also 
illustrated at all levels on a random segments of chromosome 1 (Supplementary Fig. 4A,B). 
The different cell types also displayed differences in methylation, as exemplified by the 
cluster of olfactory receptor family 2 gene members (Supplementary Fig. 5). Differential 
methylation was independent of CpG islands, absent from this region. These observations 
indicate that methylation profiles between ASCs, BMMSCs, MPCs and HSCs are similar but 
not identical. An analysis of similarly and differentially methylated genomic areas between 





Fig. R-11. Methylation profiles in ASCs, BMMSCs, MPCs and HSCs. (A) P-values (expressed in -
log10 values) for duplicate MeDIP samples for each cell type, shown here for chromosome 1. (B) 





Fig. R-11 (cont.). Methylation profiles in ASCs, BMMSCs, MPCs and HSCs. (A) P-values 
(expressed in –log10 values) for duplicate MeDIP samples for each cell type, shown here for 
chromosome 1. (B) Methylation peaks identified from P-values shown in (A).  
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Validation of the MeDIP data 
To validate the MeDIP procedure, we first assessed methylation at the levels of IP/input log2 
ratios and P-values, for known unmethylated (UBE2B, PEX13) and methylated (OXT, 
LDHC) promoters, on the basis of data from Weber et al. (Weber et al., 2007). For all cell 
types, Figure R-12 revealed DNA methylation in the promoters expected to be methylated 
from PCR and MeDIP data in fibroblasts (Weber et al., 2007);  there was no probe on the 
array for H19ICR (see Fig. R-9C). Also, all cell types showed no methylation in the 
unmethylated promoters, including UBE2B (see also Fig. R-9C for our PCR data). 
 
 
Fig. R-12. Validation of the MeDIP assay: MeDIP methylation profile of genes known to be 
methylated and unmethylated, in ASCs, BMMSCs, MPCs and HSCs. (A) Methylation profiles of two 
methylated promoters (OXT, LDHC). (B) Methylation profiles of two unmethylated promoters 
(UBE2B, PEX13). Log2 IP/input ratios, P-values and transcripts are shown.    
 
Next, we examined promoter regions that we studied by bisulfite sequencing. The log2 
IP/input ratio and P-values for the LEP, LPL, FABP4, PPARG2, MYOG and CD31 promoters 
 60
from ASCs are shown in Figure R-13A. Regions examined by bisulfite sequencing (red 
rectangles) were detected as unmethylated by MeDIP for LEP, LPL and FABP4 (Fig. R-
13A). MeDIP data for PPARG2 revealed methylation at the 5’ end of the tiled region with 
less methylation near the TSS. The region examined by bisulfite sequencing showed low 
methylation at the MeDIP level (Fig. R-13A), confirming our sequencing data (Fig. R-2). 
We also noticed that the PPARG2 promoter displayed strong methylation upstream the region 
sequenced. The MYOG promoter showed no or weak methylation by MeDIP, a result also 
confirmed by sequencing. MeDIP analysis showed enhanced methylation 3’ of the TSS (exon 
1), also in agreement with sequencing data (compare Fig. R-13A with Fig. R-2A). Lastly, 
CD31 showed methylation, as expected from sequencing. These results indicate therefore that 
MeDIP data for ASCs are supported by bisulfite sequencing. 
We concluded from these preliminary analyses that immunoprecipitation of 
methylated DNA is specific and that the data appear to be reliable. Additional validation is 
currently being performed for 20 more genes by bisulfite sequencing. 
 
DNA methylation profiles in ASCs, BMMSCs, MPCs and HSCs: comparison between 
MeDIP and bisulfite sequencing 
Lastly, we next compared the methylation profiles obtained by MeDIP in ASCs, BMMSCs, 
MPCs and HSCs, to those obtained by bisulfite sequencing (Fig. R-13B). In the region 
covered by sequencing, MeDIP showed that LEP was not or weakly methylated in ASCs, 
BMMSCs and HSCs, but displayed more methylation in MPCs than expected from 
sequencing (see Fig. R-2A). LPL was unmethylated which was also consistent with our 
previous results. FABP4 was unmethylated in ASCs and BMMSCs in agreement with 
sequencing (see above); however, it also appeared unmethylated by MeDIP in MPCs and 
HSCs, in contrast to our sequencing data. A similar discrepancy was seen for PPARG2, 
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which was detected as weakly in MPCs and HSCs by MeDIP (Fig. R-13B) but was 
methylated based on bisulfite sequencing (Fig. R-2A). As discussed below, this discrepancy 
may be explained by differences in the number of CpGs in the immunoprecipitated region. 
MeDIP profiles of PPARG2 in ASCs and BMMSCs were compatible with bisulfite 
sequencing. The MYOG promoter in ASCs showed weak methylation by MeDIP while exon 
1 showed increased methylation; this was also in complete agreement with sequencing (Fig. 
R-13B). MPCs and HSCs also displayed MeDIP methylation profiles consistent with 
sequencing. However, discrepancy was detected in BMMSCs, which showed by MeDIP 
methylation in the MYOG promoter region, a result not anticipated by sequencing (compare 
Figs. R-2A and R-13B). Lastly, MeDIP indicates that the CD31 promoter was methylated in 
ASCs and BMMSCs, in agreement with bisulfite sequencing, and to a lesser extent in MPCs. 
However, CD31 was unmethylated in HSCs, again in agreement with our sequencing data 
(compare Figs. R-8A and R-13B).  
Collectively, these results indicate that there is an overall solid correlation between 
MeDIP and bisulfite sequencing data in the regions examined. The differences can be 
explained by CpG density, which affects the immunoprecipitation (see Discussion). The 
results also argue that different MSC types can display distinct methylation profiles on 
lineage-specific promoters; however conclusions on whether DNA methylation patterns may 






Fig. R-13. MeDIP methylation profiles of LEP, LPL, FABP4, PPARG2, MYOG and CD31 in ASCs, 
BMMSCs, MPCs and HSCs. (A) Methylation patterns in ASCs. Red boxes delineate regions analyzed 
by bisulfite sequencing (Fig. R2A). A CpG island track (CpG) is shown. Note the robust fit between 
MeDIP and bisulfite sequencing data (compare with Figure 2A). (B) Methylation profiles for the 







This work tests the hypothesis that the DNA methylation pattern on promoters of lineage-
specific genes in MSCs may be used as a predictor of differentiation capacity toward a given 
lineage. Indeed, MSCs from various origins have distinct differentiation capacities and 
similarly, different ASC clones have distinct differentiation potential (Boquest et al., 2005). 
Using bisulfite sequencing and in vitro differentiation assays, we show here a relationship 
between the extent of CpG methylation of adipogenic and myogenic promoters and adipo- 
and myogenic differentiation capacity of MSCs derived from adipose tissue, bone marrow 
and muscle. This relationship, however, is dependent on the CpG content of the promoters 
examined. In addition, Wharton’s Jelly MSCs display epigenetic preference for myogenic 
differentiation, while HSCs are clearly not epigenetically programmed for adipo- or 
myogenesis. Surprisingly however, HSCs and to a lesser extent BMMSCs show a 
methylation pattern suggestive of endothelial differentiation potential. Our bisulfite 
sequencing data are corroborated by a preliminary analysis of methylation profiling of 
~24,000 promoters by MeDIP-chip. 
 
CpG methylation patterns in MSCs and HSCs 
Lineage-specific promoters show mosaic methylation 
Except for CD31, all promoter regions examined showed mosaic methylation patterns. This 
is consistent with our earlier observations based on heterogeneous methylation patterns 
between ASC donors, single cell-derived ASC clones, and individual cells within a clone 
(Noer et al., 2006; Boquest et al., 2007). Mosaic CpG methylation has also been reported in 
stem cells from single intestinal crypts (Yatabe et al., 2001), and may result from stochastic 
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methylation which accumulates in culture and from environmental, aging and health related 
factors (Esteller, 2005; Laird, 2005).  
 
Transcription factor binding elements are unmethylated  
CpG methylation is critical for maintenance of a silent chromatin state through recruitment of 
repressive chromatin modifiers to methylated DNA, and many transcription factors are 
unable to bind to their recognition site if these contain methylated CpGs. The consistent 
unmethylated state of specific CpGs suggests localization within binding sites for 
transcription factors. In the LEP promoter, three Sp1 elements and a CAAT enhancer binding 
protein (C/EBP) element are consistently unmethylated. We also found several key cis-
elements in unmethylated regions of the LPL promoter. These include Oct-1 (nt -46), NF-Y 
(nt -65) and CT (CCTCCCCC, nt -91 to -83) elements essential for basal promoter activity 
(Yang and Deeb, 1998; Mead et al., 2002) and a sterol-responsive element (SRE;  nt -90 to -
81), a peroxisome proliferator response element (PPRE) and Sp1/Sp3 motifs essential for 
LPL activation (Schoonjans et al., 2000). Similarly, the FABP4 and PPARG2 promoters 
contain unmethylated binding sites for C/EBP and AP1 (FABP4) and a putative binding site 
for GATA1/2 (PPARG2). Lastly, we found binding sites for Sp1, AP-2, GATA and an E-box 
(Gumina et al., 1997) in CD31, which may be unmasked by the unmethylated state of CpGs 
in HUVECs and HSCs. 
 These observations argue that in promoters, consistently unmethylated CpGs tend to 
reside within binding sites for transcription factors. These may, by binding to these elements, 
mask these CpGs and keep them unmethylated. Alternatively, CpGs may be protected from 
methylation to enable transcription factor targeting. Mutational promoter studies have indeed 
shown that manipulating the methylation state of specific CpGs affects factor binding and 
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transcription Campanero, 2000 CAMPANERO2000 /id; Comb, 1990 COMB1990 /id; 
Prendergast, 1991 PRENDERGAST1991B /id}. 
 
Relationship between promoter DNA methylation and gene activity 
CpG methylation and gene expression 
Irrespective of MSC type, the LEP and LPL promoters are unmethylated, which is consistent 
with their localization in a CpG island. Surprisingly however, LEP showed significantly more 
methylation in HSCs. The contribution of promoter DNA methylation to tissue-specific gene 
expression is uncertain (Weber et al., 2007) and most CpG islands remain unmethylated even 
in cell types that do not express the gene (Bird, 2002). Yet, methylation of CpG islands not 
associated with disease occasionally occurs. CpG islands can be differentially methylated in a 
tissue-specific manner, reflecting expression patterns (Song et al., 2005).The CpG island of 
the SERPINB5 promoter is unmethylated in cells expressing the gene, but is densely 
methylated in SERPINB5 negative cells (Futscher et al., 2002). Furthermore, a recent 
MeDIP-chip study interrogating ~16,000 RefSeq human promoters identified 3% high CpG 
promoters (HCPs) with marked methylation (Weber et al., 2007). Of note, the LEP promoter 
is an HCP, arguing that methylation of LEP in HSCs is one of the few instances where a 
CpG-rich promoter is methylated in a cell type where it is inactive. It will be interesting to 
investigate which HCP promoters in our on-going MeDIP work show differential methylation 
in MSCs, HSCs and differentiated cells.  
The FABP4 and PPARG2 promoters are low CpG promoters (LCPs). Remarkably, as 
with HCPs, their methylation state could not be correlated to expression status because they 
were not expressed in MSCs or HSCs, although they displayed distinct unmethylated (ASCs), 
moderately methylated (BMMSCs, MPCs) or strongly methylated profiles (MPCs, HSCs). 
Methylation patterns were maintained in differentiated adipocytes and muscle relative to 
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undifferentiated cells. Further, genome-wide profiling of promoter DNA methylation and 
RNAPII binding indicates that LCPs can be methylated both when active and inactive 
(Weber et al., 2007). Therefore, not only LCPs can be repressed even when unmethylated (as 
in ASCs), but a low concentration of methylated cytosines does also not preclude RNAPII 
binding and transcriptional activity. Thus, in MPCs, HSCs and WJMSCs, methylation of the 
FABP4 and PPARG2 promoters does not necessarily preclude initiation of transcription, 
which would be undetectable by RT-PCR.  
The region of the endothelial CD31 gene examined, which extended into exon 1, was 
strongly methylated in ASCs, BMMSCs, MPCs and WJMSCs, but was unmethylated in 
HSCs, as in CD31+ cells and HUVECs. The CD31 promoter itself belongs to the LCP 
category of Weber et al. (2007). Accordingly, we have shown that freshly isolated ASCs 
express CD31 (at low level) although the promoter is methylated (Boquest et al., 2007). So as 
with other LCPs, CpG methylation is compatible with low level transcription. However, in 
cells expressing high levels of CD31 mRNA and protein (CD31+ cells from the SVF and 
HUVECs), we found that CD31 exhibits a hemimethylated profile (Boquest et al., 2007). 
Therefore, although we at present do not know whether CD31 is or can be expressed in HSCs 
(work in progress), available data suggest that CD31 methylation does not preclude low level 
gene expression (without protein expression), but high level expression correlates with 
demethylation of the CD31 region examined. Whether CD31 is unmethylated in HSCs 
remains to be shown, however upregulation of CD31 expression in blood-derived CD34+ 
hematopoietic progenitors and contribution of these cells to the vasculature (Kung et al., 
2008) suggest that in endothelial cells differentiated from CD34+ cells, CD31 is likely to be 
unmethylated.  
These observations provide evidence against DNA methylation as a primary regulator 
of tissue-specific gene expression not only in differentiated cells (Jones and Takai, 2001), but 
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also in adult stem and progenitor cells. Our on-going genome-wide methylation profiling 
study of MSCs, HSCs and differentiated cells combined with gene expression array analysis 
is expected to provide deeper insights on the relationship between promoter DNA 
methylation and actual gene expression, rather than merely RNAPII binding (Weber et al., 
2007).  
 
Regulation of lineage-specific gene expression by histone modification 
If DNA methylation is not the primary determinant of gene expression, what then regulates 
gene activation or activation potential, upon stem cell differentiation? Another epigenetic 
component, namely post-translational histone modification, is a key player. In particular, 
trimethylation of H3K27, a mark of facultative heterochromatin, has recently emerged as a 
candidate for a transcriptional “brake”. Genome-wide and locus-specific ChIP analyses of 
mouse ESCs reveal that repressed but potentially active developmentally-regulated promoters 
are enriched in “bivalent” histone marks characterized by H3K4m3 and H3K27m3 (Azuara et 
al., 2006; Bernstein et al., 2006; Mikkelsen et al., 2007). H3K4m3 is a mark of active genes 
whereas H3K27m3 is associated with inactive genes. To support this view, in 
undifferentiated ESCs, Ezh2 (a PcG protein methylating H3K27) was found to occupy genes 
poised for transcription (Lee et al., 2006; Bracken et al., 2006). Observations from our 
laboratory have also identified H3K4m3 and H3K27m3 on adipogenic and myogenic 
promoters in undifferentiated ASCs, and demethylation of H3K27 selectively on adipogenic 
promoters upon adipogenic differentiation (A. Noer, L. Lindeman and P. Collas, manuscript 
submitted). This finding further supports the view that in ASCs, adipogenic promoters are 
epigenetically pre-programmed for activation upon adipogenic stimulation.  
Notably, these marks were identified on hypo- or moderately methylated promoters 
(including those examined in this study), indicating that targeting of trithorax and polycomb 
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proteins, which methylate H3K4 and H3K27 respectively, and resulting histone methylation 
are compatible with the unmethylated state of DNA. It will be interesting to unravel histone 
marks enriched on the CD31 promoter in its hypermethylated state in ASCs, and in its 
unmethylated state in HSCs relative to CD31+ cells in which it is active. These studies are 
underway.  
 
Relationship between promoter DNA methylation and differentiation 
potential 
Despite the complexity of the relationship between DNA methylation and gene expression, 
our results opens for the suggestion that methylation patterns on lineage-specific promoters 
can predict differentiation potential. This relationship may also depend on CpG content 
(Weber et al., 2007), because HCPs are mostly unmethylated regardless of their activation 
status, and the low CpG density of LCPs does not preclude promoter activation. This, 
therefore, would suggest that HCPs and LCPs constitute poor predictors of differentiation 
capacity. However, our bisulfite sequencing data suggest a positive relationship between CpG 
methylation of some of the promoters examined in undifferentiated MSCs, and differentiation 
capacity – as opposed to gene expression.  
 
Methylation patterns of FABP4 and PPARG2 predict adipogenic potential 
Adipogenic differentiation capacity may be more evident on the basis of methylation of ICPs 
than HCPs. ASCs and BMMSCs, but not MPCs, showed robust adipogenic differentiation 
capacity, confirming previous studies (Reyes et al., 2001; Zuk et al., 2002; Gimble and 
Guilak, 2003; Boquest et al., 2005). Both LEP and LPL promoters are unmethylated 
regardless of MSC type and of adipogenic potential. Thus in MSCs, methylation of these loci 
provide no information on predicting adipogenic differentiation. In HSCs however, the LEP 
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CpG island is 38% methylated and hypermethylated relative to MSCs, excluding the 
adipogenic potential of these cells.  
 The methylation states of FABP4 and PPARG2 (discussed above), however, were 
more informative. In particular, we found a correlation between the unmethylated state of 
FABP4 in ASCs and BMMSCs and adipogenic differentiation capacity of these cells, in 
contrast to MPCs in which it was hypermethylated. Adipogenic potential of WJMSCs was 
not tested in our study, but has been reported in vitro (Karahuseyinoglu et al., 2007). 
However, adipogenic differentiation of WJMSCs was achieved over a longer period 
compared to BMMSCs (Karahuseyinoglu et al., 2007), suggesting a weaker adipogenic 
potential of WJMSCs. Because FABP4 is more methylated in WJMSCs than ASCs or 
BMMSCs, it is possible however that this potential is provided by the unmethylated state of 
one CpG (No. 4) in all MSC types examined. In contrast, FABP4 is fully methylated in 
HSCs, again presumably precluding adipogenic potential and reflecting a lineage clearly 
distinct from MSCs. It would be interesting to determine whether demethylation of FABP4 
and PPARG2 by 5-azacytidine (which demethylates DNA) in HSCs would promote 
adipogenic potential.  
 
CpG methylation pattern of the MYOG promoter reveals myogenic potential of MPCs 
The MYOG promoter was hypomethylated in MPCs and WJMSCs relative to ASCs or 
BMMSCs, but was fully methylated in HSCs. One CpG (No.3, -314 nt from TSS) was 
strongly methylated in ASCs, BMMSCs and HSCs, but less methylated in WJMSCs and 
MPCs. Thus one may speculate that unmethylation of this CpG is involved in activation of 
the gene, in line with the myogenic potential of MPCs and, to a lesser extent, WJMSCs 
(Conconi et al., 2006).  
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The MYOG(E1) (exon 1) region examined was heavily methylated in ASCs, 
BMMSCs, MPCs and HSCs but displayed strong mosaicism in WJMSCs. Methylation of  
MYOG(E) is in agreement with earlier studies showing DNA methylation outside regulatory 
regions, including exons (Rabinowicz et al., 2003; Eckhardt et al., 2006; Weber and 
Schubeler, 2007). Our MeDIP data also reveal genes with a non-methylated promoter and 
methylation 3’ of the TSS (data not shown). Intragenic DNA methylation may inhibit cryptic 
transcription initiation (Weber and Schubeler, 2007). One CpG (No.1; nt +21) in MYOG(E1) 
was largely unmethylated in MPCs. Unmethylation of this CpG may be important for 
activation of the gene as it is adjacent to an E-box.  
The MYOG promoter methylation pattern correlated with differentiation potential of 
MPCs, but not ASCs or BMMSCs, into multinucleated fibers. Interestingly, mouse satellite 
cells can differentiate into adipocytes in vitro (Asakura et al., 2001; Wada et al., 2002);  
however our data show the inability of human MPCs to do so. This may be because MPCs 
are more differentiated than satellite cells and already committed to myogenesis. This may 
also reflect however a programming of satellite cells themselves to myogenesis preferably 
over adipogenesis. In addition, WJMSCs have adipogenic differentiation capacity in vitro 
(Karahuseyinoglu et al., 2007);  however, adipogenic differentiation was achieved after a 
longer period compared to BMMSCs. These observations argue that MPCs, and putatively 
the more primitive satellite cells, are epigenetically programmed for myogenesis, presumably 
by DNA methylation on, at least, the MYOG promoter. Methylation patterns of 
undifferentiated MPCs were conserved in myogenic differentiated MPCs, supporting this 
view. Other MSC types, such as those from Wharton’s Jelly, may also display methylation-
dependent myogenic potential, in contrast to ASCs, BMMSCs and as expected, HSCs.  
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Methylation of CD31 reflects limited endothelial differentiation capacity of MSCs 
Extensive methylation of CD31 strongly suggests a lack of endothelial differentiation in 
ASCs (Boquest et al., 2007), as well as BMMSCs, MPCs and WJMSCs. This is confirmed by 
the CD31 demethylation in CD31 expressing cells. In contrast, HSCs were unmethylated in 
the CD31 region examined. Endothelial differentiation of each of these cell types is currently 
being tested. BMMSCs, in contrast to other MSCs, showed unmethylated CpGs in CD31 
exon 1. These were outside binding elements for known transcription factors (Gumina et al., 
1997), perhaps because they locate to a genic rather than regulatory region. The significance 
of unmethylation of these CpGs may be related to the ability of BMMSCs to differentiate into 
endothelial cells in vitro and in vivo (Reyes et al., 2001).  
As expected, CD31 was also strongly methylated in adipocytes, muscle, fibroblasts 
and T cells. Yet, the 20% unmethylated alleles in T cells were reminiscent of the 
unmethylated state of HSCs. These alleles may also emanate from contaminating immature T 
cells or CD34+ cells (HSCs) with unmethylated CD31. Interestingly, CD34+ peripheral blood 
mononuclear cells (hematopoietic precursors;  (Ketterer et al., 1998) have been shown to 
restore blood flow to ischemic limbs (Schmeisser et al., 2001) and form microvessels in 
human skin substitutes (Kung et al., 2008), suggesting the endothelial potential of HSCs. 
Endothelial differentiation capacity of HSCs and BMMSCs is being tested in our laboratory. 
The methylation profile of CD31, however, argues against the endothelial potential of MSCs, 
in agreement with reports that contribution of MSCs to vasculature is most likely indirect and 




Differentiation plasticity of somatic stem cells 
  
The multilineage differentiation capacity of somatic stem cells makes them candidates for 
replacement cells in regenerative medicine (Verfaillie et al., 2002; Fraser et al., 2006). 
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However, such plasticity remains controversial and may vary with the cell type (including 
mode of isolation), tissue and the model systems studied.  
MSCs exhibit differentiation capacity along mesodermal and non-mesodermal 
lineages and transplanted MSCs can contribute to various tissues (Cousin et al., 2003; Kang 
et al., 2003; Cowan et al., 2004). Yet, little is known on the epigenetic commitment of MSCs 
to a specific cell or tissue type in vivo. It is to date not proven that MSCs form functional 
tissue of non-mesodermal lineages in vivo. MSCs may contribute to tissue repair indirectly by 
promoting the recruitment of endogenous cells or through paracrine mechanisms (Heil et al., 
2004; Miyahara et al., 2006; Boquest et al., 2006a). In addition, in several studies 
undifferentiated cells were treated with 5-azacytidine prior to differentiation (Wakitani et al., 
1995; Conconi et al., 2006). Thus, genes that would normally be silenced may be 
demethylated and amenable to activation. To get more knowledge on the epigenetic 
commitment of MSCs to tissue in vivo, our laboratory is currently testing an in vivo model 
system that allows tracking and recovering MSCs transplanted in tissues in order to examine 
their phenotype and epigenetic commitment to a particular lineage. 
Several hypotheses may account for the multilineage differentiation capacity of 
MSCs. One mechanism for pluripotency is transdifferentiation, whereby somatic stem cells 
from one germ layer might differentiate into cells of another germ layer. (ii) A second 
mechanism may involve a de-differentiation process, whereby somatic stem cells “revert” to 
a more primitive state, followed by re-differentiation along another lineage. A classical 
example is the replacement of lost anatomical parts in urodele amphibians, through 
dedifferentiation, proliferation and redifferentiation of epithelial cells in the wounded area 
(Brockes and Kumar, 2002). Whether such a mechanism also exists in humans is unclear, 
although the regenerative capacity of the liver may reflect the existence of such potential. (iii) 
Cell fusion can also alter cell fate, in a process where a stem cell may fuse with another 
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somatic cell to produce a heterokaryon in which genes from both cell types are expressed 
(Weimann et al., 2003). 
Another likely explanation for stem cell pluripotency is that a given tissue harbors 
multiple stem or progenitor cell types, each committed toward a preferred lineage. As 
mentioned earlier, bone marrow contains at least three distinct stem cell populations 
including HSCs, MSCs and endothelial progenitors. A rare MSC subset in bone marrow also 
seems to form tissues of all three germ layers (Jiang et al., 2002). Similarly, adipose tissue 
contains different progenitor cell types, including ASCs and CD31+ endothelial progenitors 
(Boquest et al., 2005). Furthermore, even ASCs are thought to contain multiple cell types, 
because different single cell clones differentiate into adipogenic, osteogenic or neurogenic 
pathways with various efficiencies (Boquest et al., 2005). The molecular determinants of 
these various stem cell sub-populations are not entirely determined. We have hypothesized 
that these may include a strong epigenetic component, including promoter DNA methylation. 
Our previous work (Noer et al., 2006; Boquest et al., 2006a; Boquest et al., 2007) and this 
thesis illustrate a mosaicism in DNA methylation patterns of MSCs from adipose, bone 
marrow and muscle tissues, suggesting the existence of epigenetically non-identical cells 
even within a tissue-specific population. 
 
Perspectives: extension to genome-wide methylation profiling 
Our conclusions on the use of DNA methylation as a predictor of differentiation capacity are 
at present based on a detailed analysis of CpG methylation in a handful of promoters and in a 
restricted area (300-200 bp). Extension of these data to genome-wide interrogation is 
expected to provide additional insights on this prediction.  
 As part of this work we have implemented a MeDIP approach to genome-wide 
methylation profiling of MSCs, HSCs and differentiated cells. Visual scanning of log2 
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IP/Input ratios and P-values shows high similarity between MeDIP duplicates and between 
cell types. Reproducibility between duplicates is more evident at the log2 IP/input ratios and 
at the P-value levels than at the methylation peak level, as a peak is defined by at least two 
consecutive P-values above 2. Therefore, similar methylation profiles at the P-value level 
may appear as different methylation peak profiles (Fig. R11). Once we have established a 
work-flow for these analyses, we will be able to experimentally adjust the offset for defining 
peaks based on values that are biologically relevant. Indeed, methylation profiles are clearly 
similar at the P-value level, which should also be rendered at the peak level.  
The high conservation of global methylation patterns between somatic cells implies 
that few differences would be detected between MSC types. Bioinformatics analysis of these 
data is underway in collaboration with the NMC (Oslo). A critical component of this analysis 
in the frame of our study will be to bring out genes or gene cluster showing distinct 
methylation profiles between all cell types, and classify them based on ontology (functional 
grouping). 
Comparison of methylation data produced by bisulfite genomic sequencing and 
MeDIP reveals apparent discrepancies, and thereby limitations to the MeDIP approach. 
Although most comparisons reveal consistency between the two approaches (Fig. R13), a 
classical example of apparent discrepancy is illustrated by the methylation pattern of FABP4 
and PARG2 in HSCs (Figs. R2A and R13B). Whereas bisulfite sequencing reveals strongly 
methylated promoters, MeDIP does not detect any methylation. A simple explanation takes 
into account the number of methylated cytosines (recognized by the antibody and therefore 
immunoprecipitated) in the region examined, relative to the total number of CpGs. Thus, 
MeDIP handles 4 but all methylated CpGs (in the 413-bp FABP4 promoter region examined) 
exactly as 4 methylated CpGs among a much larger number of CpGs in a 413-bp area. In the 
first instance, bisulfite sequencing indicates that all four CpGs are methylated, making the 
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promoter “methylated”. MeDIP however, considers the same area as unmethylated (FABP4) 
or poorly methylated (PPARG2) (Fig. R13B). It is therefore important to remember that the 
strength of MeDIP is to provide an average methylation level over the tiled region examined, 
relative to genome average methylation. Moreover, in the arrays used in this study, average 
probe spacing was 100 bp with an oligonucleotide length of 60 bp, leaving ~40 uncovered 
(and therefore not taken into consideration) nucleotides between each probe. These 
undetected nucleotides may contain significantly methylated CpGs, contributing to the 
methylation pattern reported by bisulfite sequencing.  
We conclude thus far, therefore, that MeDIP and bisulfite sequencing analyses are 
highly complementary strategies which cannot always substitute for one another. In addition, 
MeDIP-chip data must be validated for large number of promoters, either by MeDIP-PCR 
(Weber and Schubeler, 2007) or, preferably, by an independent method such as bisulfite 
sequencing. To this end, we are currently validating ~20 methylated and unmethylated 
promoters by bisulfite sequencing. Once validation is completed and the appropriate work-
flow determined, we will be in a position to (i) identify differentially methylated promoters 
between ASCs, BMMSCs, MPCs, WJMSCs and HSCs, (ii) determine whether our 
hypothesis on methylation pattern as a prediction of differentiation capacity is verified on a 
large scale, and importantly (iii) determine to what extent DNA methylation profiles on 
lineage-specific promoters are maintained or altered in the context of differentiation. On the 
basis of our present and earlier bisulfite sequencing data (Noer et al., 2006; Boquest et al., 
2006a; Boquest et al., 2007), we anticipate greater methylation stability after differentiation 
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LIST OF ABBREVIATIONS 
 
 
ADP  Adenosine diphosphate 
ATP  Adenosine triphosphate 
ADSC  Adipose derived stem/stromal cell 
ASC  Adipose stem cell 
bp  Base pair 
BMMSC Bone marrow mesenchymal stem cell 
BSA  Bovine serum albumin 
cAMP  Cyclic adenosine monophosphate 
C/EBP  CAAT enhancer binding protein 
CFU-F  Colony forming unit fibroblast 
CHIP  Chromatin immunoprecipitation 
CpG  Cytosine-phosphate guanine dinucleotide 
DAPI  4’,6-diamidino-2-phenylindole 
DNA  Deoxyribonucleic acid 
DNMT DNA methyl transferase 
ESC  Embryonic stem cell 
FABP4 Fatty acid binding protein 4 
FACS  Fluorescence-activated cell sorting 
FCS  Fetal calf serum 
HAT  Histone acetyl transferase 
HCP  High CpG promoter 
HDAC  Histone deacetylase 
HDMase Histone demethylase 
H3K  Histone 3 lysine 
H4K  Histone 4 lysine  
HMT  Histone methyl transferase   
HSC  Hematopoietic stem cell 
HUVEC Human umbilical vein endothelial cell 
IgG  Immunoglobulin G 
IP  Immunoprecipitate 
m2  Dimethylation 
m3  Trimethylation 
LCP  Low CpG promoter 
LEP  Leptin 
LPL  Lipoprotein lipase   
MBD  Methyl CpG binding domain 
MBP  Methyl binding protein 
5-mC  5-methylcytosine 
MDSC  Muscle derived stem cell 
MeDIP Methyl DNA immunoprecipitation 
MPC  Muscle progenitor cell 
mRNA Messenger ribonucleic acid 
MSC  Mesenchymal stem cell 
MYOG Myogenin 
MYOG(E) Myogenin exon  
MYOG(P) Myogenin promoter 
NCCIT Human teratocarcinoma cell line 
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NMC  Norwegian microarray consortium 
nt  Nucleotide 
P  Passage 
PBST  Phosphate buffered saline Tween-20 
PcG  Polycomb group protein 
PCR  Polymerase chain reaction 
PLA  Processed lipoaspirate cell 
PPARγ Peroxisome proliferator- activated receptor γ 
RNA  Ribonucleic acid 
RNAi  RNA interference 
RNAPII RNA polymerase II 
RT-qPCR Reverse transcriptase quantitative polymerase chain reaction 
SGBS  Simpson-Golabi-Behmel syndrome 
SP  Side population 
TSS  Transcription start site 
WJMSC Wharton’s Jelly mesenchymal stem cell 
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Supplementary Table 1.  
Bisulfite sequencing PCR and RT-PCR primers used in this study.  
 
 
Supplementary Table 2.  
P values from Fisher’s exact tests on the percentage of methylated CpGs identified by 
bisulfite sequencing at indicated loci in ASCs, BMMSCs, WJMSCs, MPCs and HSCs. 
 
 
Supplementary Fig. 1.  
Bisulfite genomic sequencing results for the three overlapping CpGs shared between 
MYOG(P) and MYOG(E1) amplicons.  
 
 
Supplementary Fig. 2.  
Assessment of DNA fragment sizes in input DNA and MeDIP samples sent for Nimblegen 
promoter array analysis. 
 
 
Supplementary Fig. 3.  
Methylation profile of 3,400 kb fragment of chromosome 1. 
 
 
Supplementary Fig. 4.  
Similarity of methylation profiles between ASCs, BMMCs, MPCs and HSCs. 
 
 
Supplementary Fig. 5.  
A region differentially methylated in ASCs, BMMCs, MPCs and HSCs. 
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F: forward primer  
R: reverse primer  
Product 
size (bp) 
Bisulfite primers  








LEP F:  GTTTTTGGAGGGATATTAAGGATTT 
R: TAACCTACCAAAAAAAACCAACAA 
361 






MYOG(E1) F:  GGGGAATTATATTTAATTTATTGTAAA 
R: ACCTCATTCACCTTCTTAAACCTAC 
495 
PPARG2 F: GTTGAAGTTTTTAAGAAAGTAAATT 
R:AAAAAAAATATTACCACACTATCTC 
480 
   
RT-PCR primers  









GAPDH F: TTGCCATGGGTGGAATCATA 
R: TCGGAGTCAACGGATTTGGT 
148 








MYF5 F: TCTGTGGCATATACATTTGATACAT 
R: GAGAGAGCAGGTGGAGAACTACT 
177 
MYOD1 F: GGCGGAACTGCTACGAAGG 
R: GATGCGCTCCACGATGCT 
113 
MYOG F: CGTCTCCTGTTCTGGTCTCTTCC 
R: CCCTTTTCCCTGCCTGTCC 
245 
PAX3 F: GCCGACTTGGAGAGGAAGGAG 
R: GCTGTTCTGCTGTGAAGGTGGTT 
184 
PAX7 F: ATTCTTTGCCGCTACCAGGA 
R: GTCACAGTGCCCATCCTTCA 
177 
PPARG2 F: CTTCCATTACGGAGAGATCCAC 
R: AAGCGATTCCTTCACTGATACAC 
125 
   
Primers used for PCR on genomic DNA from MeDIP and input samples 
H19ICR F: GAGCCGCACCAGATCTTCAG 
R: TTGGTGGAACACACTGTGATCA 
 





Supplementary Table 2. P-values from Fisher’s exact tests on the percentage of methylated 
CpGs identified by bisulfite sequencing at indicated loci in ASCs, BMMSCs, WJMSCs, 
MPCs and HSCsa. 
 
 ASC BMMSC WJMSC MPC HSC 
LEP      
% methylation 9.7 9.7 12.6 10 40 
P value >0.1 ○b ○ ○  
 <0.001    ○ 
  >0.1 ○ ○  
  <0.001   ○ 
   >0.1 ○  
   <0.001  ○ 
    <0.001 ○ 
LPL      
% methylation 10.9 0 3.6 6.4 5.5 
P value <0.01 ○    
 >0.1  ○ ○ ○ 
   >0.1 ○ ○ 
    >0.1 ○ 
FABP4      
% methylation 15.0 22.5 52.5 80.0 80.0 
P value >0.1 ○    
 <0.001  ○ ○ ○ 
  <0.01 ○ ○ ○ 
   <0.02 ○ ○ 
    >0.1 ○ 
PPARG2      
% methylation 20.0 36.7 63.3 40.7 90.3 
P value >0.05 ○    
 <0.001  ○  ○ 
 <0.03   ○  
  <0.01 ○   
  >0.1  ○  
  <0.001   ○ 
   <0.03 ○  
   <0.001  ○ 
MYOG(P)      
% methylation 34.2 34.2 23.1 18.8 89.2 
P value >0.1 ○    
  >0.05  ○   
 <0.01   ○ ○ 
  >0.05 ○   
  <0.01  ○ ○ 
   >0.1 ○  
   <0.001  ○ 
    <0.001 ○ 
 
Supplementary Table 2 is continued on the next page. 
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Supplementary Table 2 (cont.). P-values from Fisher’s exact tests on the percentage of 
methylated CpGs identified by bisulfite sequencing at indicated loci in ASCs, BMMSCs, 
WJMSCs, MPCs and HSCsa. 
 
 
MYOG(E1)      
% methylation 75.4 89.5 63.3 88.3 96.3 
P value <0.01 ○ ○ ○ ○ 
  <0.001 ○   
  >0.05  ○ ○ 
   <0.001 ○ ○ 
    <0.03 ○ 
CD31      
% methylation 93.3 73.9 95.0 90.0 6.1 
P value <0.001 ○   ○ 
 >0.1  ○ ○  
  <0.001 ○ ○ ○ 
   >0.1 ○  
   <0.001  ○ 
    <0.001 ○ 
 
a Fisher’s exact tests were calculated using the GaphPad software 
(www.graphpad.com/quickcalcs/contingency1.cfm). 






































Supplementary Fig. 1. Bisulfite genomic sequencing results for the three overlapping CpGs shared 
between MYOG(P) and MYOG(E1) amplicons. (A) Map of the MYOG region examined. The three 
overlapping CpGs are shown in red and belong to the MYOG(E1) amplicon (red bar). (B) Bisulfite 
sequencing results (lollipop diagram) and comparison of the extent of methylation at each CpG in 3’ 
















Supplementary Fig. 2. Assessment of DNA fragment sizes in input DNA and MeDIP samples sent to 
Nimblegen for promoter array hybridization. Input and MeDIP DNA was amplified as in Fig. R9 and 
resolved by agarose gel electrophoresis. Sample names (top) are those used as identification number 
in the Nimblegen data sheet. Samples ALS01REF, ALS02REF, ALS03REF, ALS01-04, ALS07 and 
















Supplementary Fig. 3.  Methylation profile of 3,400 kb fragment of chromosome 1. Top, 
chromosome positioning (nucleotide number). Track (1): scaled log2 IP/input ratios. Track (2): P-
values, expressed in –log10. Track (3): methylation peaks. Track (4): primary transcripts. Track (5): 
TSS. Track 6,: CpG islands. Track (7): tiled regions. Note the absence of CpG methylation in CpG 














































Supplementary Fig. 4. Similarity of methylation profiles between ASCs, BMMCs, MPCs and HSCs. 
(A) log2 IP/Input ratios in a randomly chosen 105 kb segment of chromosome 1, containing 5 loci. 
Note the similarity of the hybridization profiles between cell types (only one MeDIP replicate is 
shown for each cell type; replicates not shown are identical to those shown here). (B) P-values and 
methylation peaks in another randomly chosen 400 kb segment of chromosome 1. Unmethylated and 
methylated promoters are shown. Profiles are nearly identical for all cell types. This segment does not 








Supplementary Fig. 5. A 460 kb segment of chromosome 1 showing different methylation 
profiles in ASCs, BMMSCs and MPCs on the one hand, and HSCs on the other hand. P-
values and methylation peaks are shown. The olfactory receptor family 2 gene members are 
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DNA methylation contributes to the regulation of long-term gene repression by 
enabling the recruitment of transcriptional repressor complexes to methylated cytosines. 
Several methods for detecting DNA methylation at the gene-specific and genome-wide levels 
have been developed. Methylated DNA immunoprecipitation, or MeDIP, consists in the 
selective immunoprecipitation of methylated DNA fragments using antibodies to 5-
methylcytosine. The genomic site of interest can be detected by PCR, hybridization to DNA 
arrays or by direct sequencing. This Chapter describes the MeDIP protocol and quality 
control tests that should be performed throughout the procedure.  
 





DNA methylation consists in the post-replicative addition of a methyl group to the 5 
position of a cytosine in a cytosine-phosphate-guanine (CpG) dinucleotide (Fig. 1A). CpG 
methylation alters the interaction of DNA with proteins which in turn may modulate 
transcription: it is either impaired, by methylation of activator sites, or enhanced, by 
methylation of insulators and silencers (1). CpG methylation in vertebrates is symmetrical (it 
occurs on both DNA strands) (Fig. 1B) and targets isolated or clustered CpGs. In plants, 
cytosines are methylated both symmetrically (CpG or CpNpG) and asymmetrically 
(CpNpNp), where N is any nucleotide. Drosophila melanogaster only exhibits DNA 
methylation in early stages of development, while Saccharomyces cerevisiae shows no DNA 
methylation 
CpG methylation is catalyzed by DNA methyltransferases (DNMTs). The 
maintenance DNA methyltransferase DNMT1 specifically recognizes hemi-methylated DNA 
after replication and methylates the daughter strand, ensuring fidelity in the methylation 
profile after replication (2). In contrast to DNMT1, DNMT3a and DNMT3b are implicated in 
de novo DNA methylation that takes place during embryonic development and cell 
differentiation (3), as a means of shutting down genes whose activity is no longer required as 
cells differentiate (e.g., that of pluripotency-associated genes). The fourth DNMT, DNMT2, 
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has to date no clear ascribed function in DNA methylation but has been shown to have 
cytoplasmic transfer RNA methyltransferase activity (4,5).  
 DNA methylation is a hallmark of long-term gene silencing (6,7) (Fig. 1C). The 
methyl groups create target sites for methyl-binding proteins which induce transcriptional 
repression by recruiting co-repressor complexes, histone deacetylases or histone 
methyltransferases (7). DNA methylation is essential for development (8-11), X chromosome 
inactivation (12) and genomic imprinting (13-15). The relationship between DNA 
methylation and gene expression is complex (1) and recent evidence based on genome-wide 
CpG methylation profiling highlights promoter CpG content as a component of this 
complexity (16). 
 Several approaches have been developed to analyze DNA methylation profiles. 
Protocols relying on bisulfite conversion of DNA have been recently reviewed and the widely 
used bisulfite genomic sequencing approach has been extensively improved and described 
(17). An alternative to bisulfite sequencing is the immunoprecipitation of methylated DNA, 
referred to as methylated DNA immunoprecipitation, or MeDIP (18). The principle of 
MeDIP is simple: genomic DNA is randomly fragmented by sonication and methylated 
fragments are selectively immunoprecipitated using an antibody to 5-methyl cytosine (5mC). 
Detection of a gene of interest in the methylated DNA fraction can be done by polymerase 
chain reaction (PCR), hybridization to genomic arrays (MeDIP-chip) or high-throughout 
sequencing (MeDIP-seq) (19,20). We have used MeDIP-chip for the analysis of DNA 
methylation profiles in various mesenchymal stem cell (MSC) types. This chapter describes 
the MeDIP assay it is performed in our laboratory, including control tests that can be 
performed along the way (Fig. 2). The protocol is derived from that established in Dirk 






1. 1.5-ml centrifuge tubes  
2. Magnetic rack for 1.5-ml tubes (Invitrogen cat. no. MPC-E) 
3. Probe sonicator (Sartorius Labsonic M sonicator fitted with 3-mm diameter probe, or 
similar) 
4. Thermomixer (Eppendorf, model no. 5355-28402, or similar) 
5. Table top centrifuge (Eppendorf, model no. 5424, or similar) 
6. Minicentrifuge (Merck Eurolab Galaxy Mini, model no. C1211, or similar) 
7. Vortex (VWR International, model no. 444-1372, or similar) 
8. Rotator (Science Lab, model no. Stuart SB3, or similar), placed at 4oC 
9. Thermal cycler (PCR machine) with accessories  
 
2.2. Reagents 
1. Anti-5mC antibody (Eurogentec cat. no. BI-MECY-1000; Diagenode cat. no. Mab-
5MECYT-500) 
2. Dynabeads® M-280 sheep anti-mouse IgG (Invitrogen, cat. no. 112.01)  
3. GenomePlex Complete Whole Genome Amplification (WGA) Kit (Sigma-Aldrich, 
cat .no. WGA2-50RXN) 
4. MinElute PCR Purification Kit (Qiagen cat. no. 28004) 
5. 500 mM EDTA (Sigma-Aldrich, cat. no. E9884) 
6. 1 M Tris-HCl, pH 8.0 (Sigma-Aldrich, cat. no. T3253) 
7. 5 M NaCl (Sigma-Aldrich, cat. no. S5150) 
 104
8. Triton X-100 (Sigma-Aldrich, cat. no. T8787) 
9. Bovine serum albumin (BSA) (Sigma-Aldrich cat. no.A7906) 
10. Glycogen (Sigma-Aldrich, cat. no. G1767) 
11. Proteinase K (Sigma-Aldrich, cat. no. P2308) 
12. Phosphate buffered saline (PBS) (Sigma-Aldrich, cat. no. P4417) 
13. RNase, DNase-free (Roche, cat. no. 11 119 915 001) 
14. SDS (Sigma-Aldrich, cat. no. L4509)  
15. 3 M NaAc (Sigma-Aldrich, cat. no. S8750) 
16. Phenol-chloroform isoamylalcohol (25:24:1; Invitrogen, cat. no. 15593-031) 
17. Chloroform isoamylalcohol (24:1; Sigma-Aldrich, cat. no. C0549) 
18. 96% ethanol at -20oC  
19. 70% ethanol at -20oC 
20. PCR Master Mix (Promega, cat. no. M7505) 
21. Deionized (e.g., MilliQ) water 
22. Crushed ice 
 
2.3. Buffers 
1. Cell lysis buffer: 10 mM Tris-HCl pH 8.0, 0.1 M EDTA pH 8.0, 0.5% SDS. 
2. 10x immunoprecipitation (IP) buffer: 1.4 M NaCl, 100 mM Na-Phosphate (pH 7.0), 
0.5% Triton X-100.  
3. Na-phosphate: 39 ml of 2 M NaH2PO4 (276 mg/ml), 61 ml 2 M Na2HPO4 (284 
mg/ml), 100 ml MilliQ water. This makes a 1 M Na-phosphate solution at pH 7.0.  
4. PBS: dissolve 1 tablet in 200 ml MilliQ water. 
5. PBS-BSA solution: 0.05 g BSA in 50 ml PBS (i.e., 0.1% BSA). 
6. TE buffer: 10 mM Tris-HCl, pH 8.0, 10 mM EDTA. 





3.1. Purification of Genomic DNA 
The procedure described here is for DNA purification from 106 cells harvested and 
washed by your standard protocol to obtain enough DNA for a duplicate MeDIP (see Note 
1).   
1. Suspend the cell pellet (106 cells) in 400 μl of cell lysis buffer in a 1.5-ml centrifuge 
tube. 
2. Add 1.2 μl Proteinase K solution (20 mg/ml stock) per 100 μl cell lysis buffer. 
3. Incubate at 55oC for 1 h. 
4. Add another 0.6 μl of Proteinase K solution per 100 μl cell lysis buffer and incubate at 
37oC overnight. 
5. Add one volume of phenol-chloroform isoamylalcohol, centrifuge at 15,000 g for 5 
min and transfer the aqueous phase to a clean tube. 
6. Add one volume of chloroform isoamylalcohol, centrifuge at 15,000 g for 5 min and 
transfer the aqueous phase to a clean tube. 
7. Precipitate the DNA by adding 0.1 volumes of 3 M NaAc and 2.5 volumes of 96% 
ethanol at -20°C; mix and incubate for 1 h at -20oC.  
8. Centrifuge at 20,000 g for 15 min at 4°C and remove the supernatant. 
9. Add 0.5 ml of 70% ethanol to wash the pellet, vortex and centrifuge at 20,000 g for 
10 min at 4°C. Remove the supernatant. 
10. Collect the DNA pellets (from each tube) into one tube. 
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11. Dissolve the DNA in 100 μl TE buffer per 106 cells (~50 μg DNA).   
 
3.2. RNAse Treatment of Genomic DNA 
It is imperative to treat the genomic DNA with RNase because the antibody also 
recognizes 5-methylcytidine in the context of RNA.  
1. Place 100 μl genomic DNA (~50 μg DNA) into a 1.5-ml tube. The amount of DNA to 
be RNase-treated should be that needed to continue with MeDIP.  
2. Add 6 μl RNase solution (final concentration, 30 μg/ml) and incubate for 2 h at 37oC.  
 
3.3. Fragmentation of Genomic DNA 
1. Dilute the RNase-treated DNA in a total of 200 μl in TE pH 8.0 in a 1.5-ml tube 
placed on ice.  
2. Sonicate on ice for 3 x 30 sec, with 30 sec pauses on ice between each sonication 
session, using the probe sonicator. With the Labsonic M sonicator, we use the 
following settings: cycle 0.5, 30% power (see Note 2). 
3. Repeat for each DNA sample (if relevant) while leaving the sonicated samples on 
ice. 
4. To assess fragmentation, resolve 4 μl of sonicated DNA by 1.6% agarose gel 
electrophoresis and ethidium bromide staining (Fig. 3A).  
5. If necessary, continue with sonication until the desired DNA fragment length is 
achieved.  
6. Precipitate the sonicated DNA by adding 1 μl of glycogen, 400 mM NaCl and 2 
volumes of 100% ethanol, mix and incubate at -80oC for 1 h. Thaw the tubes and 
centrifuge at 20,000 g for 15 min at 4oC. Decant the ethanol. it is important to 
remove all the ethanol. The pellet may be left to dry at room temperature for 15 min. 
7. Dissolve the DNA in 60 μl MilliQ H2O and measure DNA concentration. 
 
3.4. Immunoprecipitation of Methylated DNA 
1. Dilute 4 μg sonicated DNA in 450 μl TE buffer. Remember to store the rest of the 
DNA for input. 
2. Denature for 10 min in boiling water and immediately chill on ice for 10 min. 
3. Add 51 μl of 10x IP buffer. 
4. Add 10 μl of anti-5mC antibody and incubate for 2 h at 4oC on a rotator set to 40 rpm. 
5. Pre-wash 40 μl of Dynabeads with 800 μl PBS-BSA for 5 min at room temperature 
with shaking, 800 rpm on Thermomixer. 
6. Place on magnetic rack to collect the beads; remove the PBS-BSA and repeat the 
wash (step 5) with 800 μl PBS-BSA 
7. Collect the beads with a magnetic rack and resuspend in 40 μl of 1x IP buffer. 
8. Add Dynabeads to the sample and incubate for 2 h at 4oC on a rotator set at 40 rpm. 
9. Place the tube on a magnetic rack to collect the beads and wash with 700 μl 1x IP 
buffer for 10 minutes at room temperature on a Thermomixer at 950 rpm. 
10. Repeat wash step 9 once. 
11. Transfer the content of the tube to a clean 1.5-ml tube. This tube shift step eliminates 
any non-specifically bound DNA stuck on the tube wall which may give rise to 
background in the analysis. 
12. Place the tube on the magnetic rack, collect the beads and wash once with 700 μl IP 
buffer at room temperature on a Thermomixer at 950 rpm. 
13. Collect the beads with the magnetic rack and resuspend in 250 μl Proteinase K 
digestion buffer.  
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14. Add 3.5 μl proteinase K solution (20 mg/ml stock). 
15. Incubate for 3 h at 50oC on a Thermomixer at 950 rpm. 
16. Extract DNA once with 250 μl phenol-chloroform isoamylalcohol and once with 250 
μl chloroform isoamylalcohol.  
17. Precipitate DNA by adding 20 μl of 5 M NaCl stock (400 mM final concentration), 1 
μl glycogen and 500 μl 100% ethanol; mix and incubate at -80oC for 1 h. Centrifuge 
at 20,000g for 15 min at 4oC. Make sure to remove all ethanol after centrifugation. 
18. Dissolve the DNA in 15 μl H2O overnight at 4oC. 
19. Measure DNA concentration with a Nanodrop and store at -20oC. 
 
3.5. Amplification of Precipitated DNA 
Following immunoprecipitation, the yield of MeDIP DNA is low (300-450 ng in our 
hands) and incompatible with hybridization to microarrays (Nimblegen promoter arrays 
require 2 μg DNA per array). A genomic DNA amplification step, followed by a clean up, are 
therefore introduced in the protocol. For MeDIP and input DNA amplification, we use the 
Sigma WGA2 GenomePlex
 
Complete Whole Genome Amplification Kit but omit the DNA 
fragmentation step (see Note 3). 
 
3.5.1. Amplification of precipitated and input DNA 
1. Place 11 μl (i.e., 100 ng) of MeDIP DNA into a 0.6-ml tube, and add 2 μl of 1x 
library preparation buffer provided with the WGA2 kit, and 1 μl of library 
stabilization solution.  
2. Repeat steps 1 and 2 with the input DNA sample. 
3. Vortex thoroughly, centrifuge briefly and denature by placing in a thermal cycler at 
95oC for 2 min. 
4. Place the samples on ice, centrifuge briefly and return the samples on ice. 
5. Add 1 μl of library preparation enzyme solution provided with the WGA2 kit, vortex 
well and centrifuge briefly. 
6. Place samples in a thermal cycler and run the following program: 16oC for 20 min, 
24oC for 20 min, 37oC for 20 min, 75oC for 5 min and hold at 4oC. 
7. Remove samples from the thermal cycler, centrifuge briefly and either freeze and 
store at -20oC (for up to 3 days) or proceed with amplification. 
8. Prepare a PCR master mix by adding to the 15-μl reaction from step 7: 7.5 μl of 10x 
amplification master mix, 47.5 μl nuclease-free water and 5 μl of WGA DNA 
polymerase (provided with the WGA2 kit). 
9. Vortex thoroughly and centrifuge briefly. 
10. Incubate samples in a thermal cycler with the following program: 95oC for 3 min and 
14 cycles of 94oC for 15 sec (dematuration) and 65oC for 5 min (annealing/extension). 
Hold the reaction at 4oC when completed. The amplified sample can be stored at -
20oC, similarly to genomic DNA. 
 
3.5.2. Clean up the amplified DNA 
 The amplified DNA needs to be cleaned up regardless of the mode of analysis that 
follows. We use the MinElute PCR Purification Kit protocol from Qiagen as per 
manufacturer’s instructions. The kit is designed for purification of DNA fragments ranging 
from 70 bp to 4 kb and thus is well suited for fragmented MeDIP and input DNA fragments.  
1. Add 5 volumes of PBI buffer provided with the kit to the amplified DNA sample, i.e., 
75 μl buffer to the 15 μl sample of step 10 in Subheading 3.5.1, and mix. 
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2. Make sure the color of the mixture is yellow, indicative of the right pH. If it is not 
yellow, at 10 μl of 3 M sodium acetate, pH 5.0, and mix. The mixture will turn 
yellow. 
3. Place a MinElute column in a provided 3 ml collection tube in a rack, add the DNA 
sample from step 2 and centrifuge for 1 min to bind DNA to the membrane in the 
column. 
4. Discard the flow-through and return the column back into the same tube. 
5. Add 750 μl buffer PE provided with the kit (wash buffer) and centrifuge for 1 min. 
6. Discard the flow-through, return the column to the tube and centrifuge again for 1 min 
at full speed. 
7. Place the MinElute column into a clean 1.5 ml centrifuge tube. 
8. Add 10 μl MilliQ water to the center of the membrane, let the column stand for 1 min 
and centrifuge for 1 min. The eluate volume should be ~9 μl starting from 10 μl 
elution solution (see Note 4).  
 
3.6. Analysis of Precipitated DNA 
Analysis of DNA methylation can be performed by PCR, hybridization to genomic 
arrays or by high-throughout sequencing (16,18,21-23).  
 
3.6.1. Assessment of DNA fragment size distribution 
 Before any analysis of MeDIP DNA we routinely check that the range of fragment 
sizes is conserved between multiple samples. This is done by 1.2% agarose gel 
electrophoresis of an aliquot of amplified and cleaned up DNA. Figure 3B shows that all 
input and MeDIP DNA samples display fragment sizes uniformly ranging from 200 to ~850 
bp, with most fragments around 300 bp.  
 
3.6.2. PCR analysis 
 It is recommended to verify the specificity of the MeDIP by PCR analysis of 
immunoprecipitated and input DNA samples prior to fluorescent labeling and array 
hybridization, primarily due to the labor and costs involved. Both input (positive control) and 
MeDIP DNA samples should be analyzed using primer pairs to loci known to be methylated 
or unmethylated (such as housekeeping genes). As methylated control locus, we use the H19 
imprinted control region (H19ICR) with the following primer pair: 5’-
GAGCCGCACCAGATCTTCAG-3’ and 5’-TTGGTGGAACACACTGTGATCA-3’ (annealing 
temperature 60oC). As unmethylated control locus, we use primers to the promoter of the 
housekeeping UBE2B gene with the following primer pair: 5’-
CTCAGGGGTGGATTGTTGAC-3’ and 5’-TGTGGATTCAAAGACCACGA-3’ (annealing 
temperature 60oC). Figure 3C illustrates the result of MeDIP and input DNA sample PCR 
analysis using the above primers for three different cell types. Note that in NCCIT embryonal 
carcinoma cells, the H19ICR is unmethylated (Fig. 3C). A list of candidate methylated and 
unmethylated loci and respective PCR tests after MeDIP has been recently published (16).  
 
3.6.3. Microarray-based analysis 
 Several commercial platforms exist for hybridization of MeDIP samples. Choice of 
platform depends on the experimental objective (e.g., investigation of CpG islands 
specifically, or promoters), array design, probe density, previous experience and cost. We 
have used Nimblegen human HG18 RefSeq Promoter arrays (cat. no. C4226-00-01; 
www.nimblegen.com) in an investigation of methylation profiles in the promoters of various 
cell types (see also Ref. (16) for an earlier version of these arrays). Figure 4 illustrates the 
confirmation that MeDIP-array results match the PCR data (see Fig. 3C for the UBE2B 
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promoter methylation) and the PCR and array data of Weber and colleagues (16). In addition, 
Figure 5 shows the MeDIP methylation profiles of several adipogenic, myogenic and 
endothelial gene promoters in human adipose tissue stem cells. These profiles are in 
agreement with CpG methylation patterns reported by bisulfite genomic sequencing (24-26).  
 
3.6.4. High-throughout Sequencing 
 By similarity to chromatin immunoprecipitation (ChIP)-sequencing approaches (27), 
it is possible to analyze MeDIP DNA in an unbiased manner by direct quantitative high-





1. We find that 106 cells are usually sufficient for one duplicate MeDIP. Note that the 
extent of DNA recovery may vary between cell types.  
 
2. Sonication should produce DNA fragments of ~300 to 1,000 bp (Fig. 3A). DNA 
fragments of less than 200 bp will be difficult to label when analyzed by microarray. 
The sonication protocol reported here is suitable for a variety of cell lines and primary 
cell types such as NCCIT cells, 293T cells, skin fibroblasts, keratinocytes, adipose-, 
bone marrow- and muscle-derived MSCs or hematopoietic stem cells). Optimization 
of sonication conditions may be required for a different cell type and other sonicator 
models. Samples should not foam as this reduces sonication efficiency. 
 
3. DNA amplification: The Sigma WGA2 DNA amplification procedure includes a 
three-step process: DNA fragmentation, library generation and PCR amplification. 
The first two steps, fragmentation and library generation, are recommended by the 
manufacturer to be carried out without interruption. However, in the MeDIP assay, 
the DNA to be amplified is already fragmented, so we omit the fragmentation step of 
the WGA2 protocol and start at the library preparation step. The WGA2 kit 
recommends starting with 10-100 ng DNA; however we consistently start with 100 ng 
DNA. At the end of the amplification procedure as described in Subheading 3.5.1., 
we obtain 20 μl of DNA at ~500 ng/μl, or a total of approximately 10 μg DNA.  
 
4. We elute DNA with MilliQ water, as performed by Farnham and colleagues (28). 
However, it should be possible to use the Qiagen elution buffer (EB) buffer provided 
with the clean up kit. We do not recommend eluting with TE buffer because EDTA 





 1.  Jones, P. A. and Takai, D. (2001) The role of DNA methylation in mammalian 
epigenetics. Science 293, 1068-1070. 
 2.  Jaenisch, R. and Bird, A. (2003) Epigenetic regulation of gene expression: how the 
genome integrates intrinsic and environmental signals. Nat. Genet. 33 Suppl, 245-
254. 
 109
 3.  Turek-Plewa, J. and Jagodzinski, P. P. (2005) The role of mammalian DNA 
methyltransferases in the regulation of gene expression. Cell Mol. Biol. Lett. 10, 631-
647. 
 4.  Rai, K., Chidester, S., Zavala, C. V., Manos, E. J., James, S. R., Karpf, A. R., Jones, 
D. A. and Cairns, B. R. (2007) Dnmt2 functions in the cytoplasm to promote liver, 
brain, and retina development in zebrafish. Genes Dev. 21, 261-266. 
 5.  Goll, M. G., Kirpekar, F., Maggert, K. A., Yoder, J. A., Hsieh, C. L., Zhang, X., 
Golic, K. G., Jacobsen, S. E. and Bestor, T. H. (2006) Methylation of tRNAAsp by 
the DNA methyltransferase homolog Dnmt2. Science 311, 395-398. 
 6.  Hoffman, A. R. and Hu, J. F. (2006) Directing DNA methylation to inhibit gene 
expression. Cell Mol. Neurobiol. 26, 425-438. 
 7.  Klose, R. J. and Bird, A. P. (2006) Genomic DNA methylation: the mark and its 
mediators. Trends Biochem. Sci. 31, 89-97. 
 8.  Morgan, H. D., Santos, F., Green, K., Dean, W. and Reik, W. (2005) Epigenetic 
reprogramming in mammals. Hum. Mol. Genet. 14, R47-R58. 
 9.  Young, L. E. and Beaujean, N. (2004) DNA methylation in the preimplantation 
embryo: the differing stories of the mouse and sheep. Anim. Reprod. Sci. 82, 61-78. 
 10.  Mann, J. R. (2001) Imprinting in the germ line. Stem Cells 19, 287-294. 
 11.  Razin, A. and Shemer, R. (1995) DNA methylation in early development. Hum. Mol. 
Genet. 4, 1751-1755. 
 12.  Hellman, A. and Chess, A. (2007) Gene body-specific methylation on the active X 
chromosome. Science 315, 1141-1143. 
 13.  Tremblay, K. D., Saam, J. R., Ingram, R. S., Tilghman, S. M. and Bartolomei, M. S. 
(1995) A paternal-specific methylation imprint marks the alleles of the mouse H19 
gene. Nat. Genet. 9, 407-413. 
 14.  Sapienza, C., Peterson, A. C., Rossant, J. and Balling, R. (1987) Degree of 
methylation of transgenes is dependent on gamete of origin. Nature 328, 251-254. 
 15.  Reik, W., Collick, A., Norris, M. L., Barton, S. C. and Surani, M. A. (1987) Genomic 
imprinting determines methylation of parental alleles in transgenic mice. Nature 328, 
248-251. 
 16.  Weber, M., Hellmann, I., Stadler, M. B., Ramos, L., Paabo, S., Rebhan, M. and 
Schubeler, D. (2007) Distribution, silencing potential and evolutionary impact of 
promoter DNA methylation in the human genome. Nat. Genet. 39, 457-466. 
 17.  Clark, S. J., Statham, A., Stirzaker, C., Molloy, P. L. and Frommer, M. (2006) DNA 
methylation: bisulphite modification and analysis. Nat. Protoc. 1, 2353-2364. 
 110
 18.  Weber, M., Davies, J. J., Wittig, D., Oakeley, E. J., Haase, M., Lam, W. L. and 
Schubeler, D. (2005) Chromosome-wide and promoter-specific analyses identify sites 
of differential DNA methylation in normal and transformed human cells. Nat. Genet. 
37, 853-862. 
 19.  Zilberman, D. and Henikoff, S. (2007) Genome-wide analysis of DNA methylation 
patterns. Development 134, 3959-3965. 
 20.  Jacinto, F. V., Ballestar, E. and Esteller, M. (2008) Methyl-DNA 
immunoprecipitation (MeDIP): hunting down the DNA methylome. Biotechniques 
44, 35, 37, 39. 
 21.  Penterman, J., Zilberman, D., Huh, J. H., Ballinger, T., Henikoff, S. and Fischer, R. L. 
(2007) DNA demethylation in the Arabidopsis genome. Proc. Natl. Acad. Sci U. S. A 
104, 6752-6757. 
 22.  Zilberman, D., Gehring, M., Tran, R. K., Ballinger, T. and Henikoff, S. (2007) 
Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an 
interdependence between methylation and transcription. Nat. Genet. 39, 61-69. 
 23.  Jacinto, F. V., Ballestar, E., Ropero, S. and Esteller, M. (2007) Discovery of 
epigenetically silenced genes by methylated DNA immunoprecipitation in colon 
cancer cells. Cancer Res. 67, 11481-11486. 
 24.  Boquest, A. C., Noer, A., Sorensen, A. L., Vekterud, K. and Collas, P. (2007) CpG 
methylation profiles of endothelial cell-specific gene promoter regions in adipose 
tissue stem cells suggest limited differentiation potential toward the endothelial cell 
lineage. Stem Cells 25, 852-861. 
 25.  Noer, A., Sørensen, A. L., Boquest, A. C. and Collas, P. (2006) Stable CpG 
hypomethylation of adipogenic promoters in freshly isolated, cultured and 
differentiated mesenchymal stem cells from adipose tissue. Mol. Biol. Cell 17, 3543-
3556. 
 26.  Noer, A., Boquest, A. C. and Collas, P. (2007) Dynamics of adipogenic promoter 
DNA methylation during clonal culture of human adipose stem cells to senescence. 
BMC Cell Biol. 8, 18-29. 
 27.  Mikkelsen, T. S., Ku, M., Jaffe, D. B., Issac, B., Lieberman, E., Giannoukos, G., 
Alvarez, P., Brockman, W., Kim, T. K., Koche, R. P., Lee, W., Mendenhall, E., 
O'Donovan, A., Presser, A., Russ, C., Xie, X., Meissner, A., Wernig, M., Jaenisch, R., 
Nusbaum, C., Lander, E. S. and Bernstein, B. E. (2007) Genome-wide maps of 
chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-560. 
 28.  Acevedo, L. G., Iniguez, A. L., Holster, H. L., Zhang, X., Green, R. and Farnham, P. 







The basis for this MeDIP protocol has been the procedure established in Dirk Schübeler’s 
laboratory (Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland) by 
Michaël Weber and Dirk Schübeler and posted on the Epigenome Network of Excellence 
website (http://www.epigenome-noe.net/researchtools/protocol.php?protid=33). We are also 




Fig. 1. Principles of DNA methylation. (A) Mechanism of DNA methylation. (B) CpG 
methylation is symmetrical and occurs on both DNA strands. (C) DNA methylation 
correlates with long-term gene repression.  
 
Fig. 2. The MeDIP assay. Genomic DNA is purified from cells, fragmented to ~300-1,000 bp 
by sonication, and 5-mC enriched fragments are immunoprecipitated using an anti-5mC 
antibody. Precipitated and input DNA are amplified. For array-based analysis, the input DNA 
is labeled with Cy3 while and MeDIP (precipitated) DNA is labeled with Cy5.  
 
Fig. 3. Quality assessments of DNA during the MeDIP assay. (A) Assessment of 
fragmentation by sonication. Both intact (non-fragmented) and sonicated DNA samples from 
adipose stem cells (ASCs), bone marrow mesenchymal stem cells (BMMSCs) and muscle 
progenitor cells (MPCs) were analyzed by electrophoresis in 1.2% agarose and ethidium 
bromide staining. (B) Assessment of input and MeDIP DNA fragment size distribution and 
uniformity after amplification. Input and MeDIP DNA samples from ASCs, BMMSCs and 
MPCs were amplified, purified and resolved by electrophoresis in 1.2% agarose and ethidium 
bromide staining. Note the uniformity of the fragment sizes. Such samples are ready for 
processing for labeling and microarray hybridization. (C) PCR analysis of specificity of the 
MeDIP assay. Input and MeDIP DNA was analyzed by PCR using primers specific for the 
human H19 Imprinting Control Region (H19 ICR), which is methylated in somatic cells but 
not in male germ-cell-derived embryonal carcinoma NCCIT cells, and for the human UBE2B 
(ubiquitin-conjugating enzyme E2B) locus, which is unmethylated. DNA from ASCs, 
BMMSCs and NCCIT cells was used in this analysis. PCR products were resolved by 
agarose gel electrophoresis and stained with ethidium bromide.  
 
Fig. 4. Validation of the MeDIP assay: MeDIP methylation profile of genes known to be 
methylated and unmethylated, in adipose stem cells (ASCs), bone marrow MSCs 
(BMMSCs), muscle progenitor cells (MPCs) and hematopoietic stem cells (HSCs). (A) 
Methylation profiles of two known methylated promoters (OXT, LDHC). (B) Methylation 
profiles of two known unmethylated housekeeping gene promoters (UBE2B, PEX13). Log2 
IP/input ratios, P-values and transcripts are shown.    
 
Fig. 5. MeDIP methylation profiles of the LEP, LPL, FABP4, PPARG2, MYOG and CD31 
promoters in adipose stem cells. Rectangle boxes delineate genomic regions analyzed earlier 
by bisulfite sequencing (24-26). A CpG density track (CpG) is also shown. 
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